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ABSTRACT 
The progesterone receptor (PR) is an important member of the nuclear receptor 
superfamily of transcription regulatory proteins. It plays vital roles in a diverse set of 
biological processes, from homeostasis to reproduction. PR’s major function involves 
binding of liganded receptor to DNA and regulating the expression of progesterone-
responsive genes. Much of what we have learned about PR action has been based on 
studies using progestins and anti-progestins that bind in the receptor’s ligand binding 
pocket. PR-specific antagonists can potentially serve as useful treatments for 
endometriosis, uterine fibroids, and breast cancer. We have identified a set of small 
molecules that uniquely act outside of PR’s ligand-binding pocket and selectively inhibit 
PR activity in intact cells. These small molecules inhibit PR-mediated induction of the 
mouse mammary tumor virus (MMTV)-luciferase reporter and endogenous alkaline 
phosphatase activity in T47D cells with IC50s in the low micromolar range. They inhibit 
PR with limited cross-reactivity for inhibiting other steroid receptors, estrogen receptor 
(ER), glucocorticoid receptor (GR), and androgen receptor (AR). Our in vitro studies 
show that these inhibitors do not act by blocking PR binding to the progesterone 
response element on DNA. One class of inhibitors described here act, in part, by 
altering the nuclear localization of activated receptor, leading to reduced DNA binding in 
cells. A different class of small molecules does not reduce DNA binding, but 
preferentially inhibits PR-mediated gene transactivation. Identifying novel sites and 
modes of action of small molecule inhibitors of progesterone receptor will be useful in 
dissecting details of the mechanisms of PR action. These sets of noncompetitive 
inhibitors that demonstrate specificity for PR over GR show promise in their ability to 
	  	   iii	  
distinguish between the roles of PR and GR-mediated gene transcription, and have long 
term potential for therapeutic development. 
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CHAPTER I: 
INTRODUCTION 
 
PHYSIOLOGY OF PROGESTERONE 
Progesterone is a vital hormone that coordinates female reproductive activity. 
During ovulation, to prepare the uterus for implantation, progesterone levels increase 
and convert the uterine endometrium to its secretory stage. At the same time, 
progesterone promotes the thickening of the vaginal epithelium and cervical mucosa, 
making it impenetrable to sperm. If pregnancy does not occur, progesterone levels will 
decrease, leading to menstruation. Normal menstrual bleeding is progesterone-
withdrawal bleeding. During implantation and gestation, progesterone appears to 
decrease the maternal immune response to allow for acceptance of the pregnancy. To 
maintain the pregnancy, progesterone decreases contractility of the uterine smooth 
muscle. In addition, progesterone inhibits lactation during pregnancy. A drop in 
progesterone levels is believed to help initiate the onset of labor. This fall also triggers 
milk production following delivery. At the end of the reproductive cycle, progesterone is 
critical in signaling mammary epithelial proliferation, resulting in pregnancy-induced 
mammary morphogenesis in adults (1; 2). 
Progesterone has numerous tissue-specific effects in non-reproductive target 
tissues that can be contrary to those in the uterus and breast. It also has functions in the 
central nervous system (CNS) (3). Progesterone, like pregnenolone and 
dehydroepiandrosterone, belongs to the group of neurosteroids, which can be 
synthesized within the central nervous system. Neurosteroids affect synaptic 
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functioning, are neuroprotective, and affect myelination (4). They have recently been 
investigated for their potential to improve memory and cognitive ability. In the brain, 
spinal cord and peripheral nerves, progesterone is synthesized from its direct precursor 
pregnenolone, which is found in the CNS. Although there are only a few studies 
addressing the biological significance of progesterone synthesis in the brain, the 
autocrine/paracrine actions of locally synthesized progesterone are likely to play an 
important role in the viability of neurons and in the formation of myelin sheaths. 
Progesterone may exert its neuroprotective effects by regulating expression of specific 
genes in neurons and glial cells, which may become hormone-sensitive after injury (5). 
Local synthesis of progesterone in the brain and the neuroprotective and promyelinating 
effects of this neurosteroid offer interesting therapeutic possibilities for the prevention 
and treatment of neurodegenerative diseases, for accelerating regenerative processes 
and for preserving cognitive functions during aging. 
 
NUCLEAR RECEPTORS 
The effects of progesterone are mediated by the progesterone receptor (PR) 
through transcriptional regulation and/or the initiation of rapid signaling cascades in the 
cytoplasm (6; 7). PR is an important member of the nuclear receptor super-family of 
transcription regulatory proteins. Within the nuclear receptor super-family is the steroid 
receptor sub-family that includes: PR, androgen receptor (AR), glucocorticoid receptor 
(GR), estrogen receptor (ER), and mineralocorticoid receptor (MR). 
Nuclear receptors consist of 6 major domains (8; 9) (Figure 1.1). The A-B domain 
is the N-terminal regulatory domain that contains activation function 1 (AF-1). 
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Transcriptional activation by AF-1 is ligand-independent and normally very weak, but 
works with AF-2 in the E domain to produce a more robust upregulation of gene 
expression (10). The A-B domain is highly variable in sequence between the nuclear 
receptors. The C domain is the DNA-binding domain (DBD). This highly conserved 
domain contains two zinc fingers that bind to specific DNA sequences called hormone 
response elements (HRE). The D domain, or hinge region, is thought to be a flexible 
domain that connects the DBD with the LBD and influences intracellular trafficking and 
subcellular distribution (11; 12). The E domain is the ligand-binding domain (LBD). It is 
moderately conserved in sequence and highly conserved in structure. The structure of 
the LBD is referred to as an alpha helical sandwich fold in which three anti-parallel 
alpha helices form a ligand binding cavity that is flanked by two alpha helices on one 
side and three on the other. The LBD, with the DBD, creates the dimerization interface 
of the receptor, and is also the site of most (13) and (11; 12) protein binding. The LBD 
contains the AF-2, whose action is dependent on the presence of bound ligand, giving 
this domain its name. Lastly, the F domain is the variable C-terminal domain. 
Steroid receptors are tissue-specific in circulation and some are cytosolic in their 
inactive state. As small lipophilic hormones diffuse across the cell membrane, or are 
actively transported, they bind to their respective nuclear receptor. This causes a 
change in the conformation of the receptor, which triggers a number of downstream 
events that result in the up or downregulation of gene expression. 
Some steroid receptors are sequestered in the cytosol by heat shock protein 
complexes. Before ligand binding, they are inactive and in a conformation that exposes 
their LBD and shields the zinc finger domains of the DBD. Upon ligand binding, they 
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shift conformation, releasing the receptor from the chaperone complex and resulting in 
translocation into the nucleus. Hormone-bound receptors then form homodimers that 
bind to specific HREs in DNA. Each monomer of the homodimer binds one of two DNA 
half-sites, separated by a variable number of nucleotides. This unique HRE is a perfect 
or imperfect palindrome. The ligand-receptor-DNA complex then signals the recruiting of 
coactivators or corepressors that will regulate transcription of the target genes and other 
downstream effects (14). Figure 1.2 depicts the transcriptional activity of PR in cells. 
 
PROGESTERONE RECEPTOR 
In humans, two isoforms of progesterone receptor (PR-A and PR-B) are 
transcribed from one distinct, estrogen-inducible promoter, containing different start 
sites within a single PR gene. The result is the B-upstream segment (BUS), which is an 
additional 164 amino acids at the N-terminus of hPR-B (120 kDa) that is missing in 
hPR-A (94 kDa). Although the BUS is the only difference between the two isoforms, it 
confers unique function that distinguishes the two receptors. A third activation function 
(AF-3) is located in the BUS and typically makes PR-B a stronger activator of 
transcription than PR-A (Figure 1.1) (15). However, PR-A can be a stronger activator 
depending on the cell type and the target promoter (13). Although both isoforms are co-
expressed in most target tissues, their ratios and physiological roles differ based on 
environmental context. Receptor knock-out studies in mice have shown that PR-A does 
not affect the response of the mammary gland or thymus to progesterone, but is 
necessary for normal ovarian and uterine function for female fertility. Conversely, PR-B 
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does not affect ovarian, uterine or thymic responses to progesterone, but is needed for 
mammary ductal morphogenesis and alveologenesis during pregnancy (13). 
In most cell lines, PR-A functions as a transcriptional repressor of progesterone-
responsive promoters, whereas PR-B functions as a transcriptional activator of the 
same genes (16–18). A specific inhibitory domain mapped to the extreme N-terminus of 
PR-A has been linked to its repressive function. Interestingly, this domain’s activity is 
masked in PR-B, suggesting that transcription factor recruitment due to AF-3 may play a 
role in their functional differences (10). For example, Giangrande & McDonnell observed 
that the corepressor SMRT (silencing mediator of retinoid and thyroid receptors) 
interacts more tightly with PR-A than with PR-B. 
Characterization of the BUS has identified that two LXXLL motifs and tryptophan 
140 are required for PR-B activity. When these elements are mutated, a vital interaction 
between AF-3 and the other two AFs is eliminated, crippling the activity of the receptor 
(19; 20). AF-3 sufficiency for DNA binding has also been demonstrated when the BUS 
is linked to the DBD of the structurally similar GR (11). This allosteric communication 
between the DBD, N-terminal functional regions, and the AF-2 in the LBD has taught us 
a great deal about the unique properties of the progesterone receptors. However, there 
is still much to learn since their identification in the 1970s. 
Progesterone receptor, like some other members of the steroid receptor family, 
has been reported to stimulate rapid effects in signal transduction pathways 
independent of its role in gene transcription. This extra-nuclear activity occurs on a time 
scale of seconds to minutes, much too fast to involve gene transcription, and has been 
demonstrated using isolated cell membranes or enucleated cytoplasts that do not 
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contain a nucleus (10). These rapid extra-nuclear, or nongenomic, activities include 
stimulating second messenger production, ion channels, and protein kinase cascades. 
When PR is localized predominantly to the cell membrane by tagging with palmitic acid, 
or to the cytoplasm by deletion of its nuclear localization signal, the receptor mediates 
rapid progestin-induced activation of Src/MAPK and fails to mediate activation of PRE 
reporter genes. The involvement of PR in the Src/ras/raf/MAP kinase (Erk) pathway has 
helped to distinguish the extra-nuclear actions of PR from those of other steroid 
receptors (Figure 1.2). Src is a key proximal component to extracellular-membrane 
signaling that regulates proliferation, differentiation, adhesion, migration, cell-cell 
interactions, and even apoptosis (21). The Src family proteins are non-receptor tyrosine 
kinases that contain a unique N-terminal domain, a regulatory region that contains an 
SH3 and an SH2 domain, a linker region, and a C-terminal catalytic domain (22). Upon 
activation, the unique N-terminal domain is myristoylated and inserts into the cell 
membrane. SH2 domains recognize and bind tyrosine phosphorylated peptides, 
whereas SH3 domains recognize short contiguous poly-proline motifs (PXXPXR) that 
form a left-handed helical conformation. This motif in PR (PPPPLPPR) is located in the 
N-terminus (aa421-428). Not only is this sequence necessary and sufficient to mediate 
the SH3 domain interaction, but point mutations in this motif successfully abrogate Src 
pathway signaling, but not progestin-induced transcription regulation (23). One 
example, and well-characterized nongenomic role of progesterone, has been its ability 
to induce germ cell maturation. High concentrations of progesterone are secreted into 
the cumulus oophorous and follicular fluid surrounding the egg. This stimulates a rapid 
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influx of extracellular calcium and an efflux of chloride ions that are essential for 
initiating the acrosome reaction for fertilization (24). 
Progesterone receptor knock-out (PRKO) mice have been a valuable tool used to 
distinguish tissue specific roles and pathways of PR action. Progesterone is also an 
essential mediator of ovulation. Using PRKO mice, this receptor was shown to be the 
determining factor that stimulates the release of luteinizing hormone (LH). Although 
ovarian follicles in PR knockout mice undergo normal development and contain a fully 
functional oocyte, they fail to rupture and are found in abundance in the ovary. There is 
no evidence of corpora lutea in these mice (25). In the breast, PRKO mice exhibited a 
significant reduction in mammary tumor susceptibility (1), highlighting an important role 
for progesterone signaling in mammary cell growth and tumorigenesis (26). 
 
PROGESTERONE RECEPTOR AND DISEASE 
Uterine leiomyoma (fibroids) are the most common tumors in women of 
reproductive age. Symptoms include irregular uterine bleeding, pressure sensation in 
the lower abdomen, pelvic pain, recurrent pregnancy loss, and even infertility. 
Symptoms associated with fibroids usually dissipate with menopause, suggesting that 
these tumors are dependent on ovarian steroids (27). Despite the fact that fibroids are 
benign, they are the most common cause for hysterectomy and have a major impact on 
women’s health and quality of life. Currently, there are no effective long-term 
medications for their treatment. Fibroids are hormonally responsive, and have been 
linked to the upregulation of key genes that regulate apoptosis and proliferation, like bcl-
2 and c-myc, respectively. Both genes contain functional PREs (28). Because 
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progesterone has also been shown to inhibit tumor necrosis factor-α (TNFα) and insulin-
like growth factor-1 (IGF-1), research suggests that it may have both inhibitory and 
stimulatory effects in leiomyoma (29). 
Impaired reproductive development and infertility are well-known consequences 
of progesterone hormone and/or receptor deficiency, however, their potential roles in 
cancers are a more recent focus. Because PR is an estrogen-inducible gene, it has 
been suggested that its presence may serve as an indicator of ER functional capacity 
and tumor differentiation state (30). High levels of PR in breast cancers have been 
correlated with poor survival and expression profiling of PR has been shown to have 
some predictive value (31; 32). In post-menopausal, tamoxifen-treated patients with ER-
positive tumors, the predominance of PR-A over PR-B expression appears to 
demonstrate more cancers that are likely to recur and are more aggressive (33). 
Because the PR isoforms exhibit tissue-specific expression and functionality in tumors, 
the role of PR in breast and uterine cancer is not well understood (26). However, recent 
studies suggest that PR plays an important anti-inflammatory role in breast cancer via 
ligand-dependent and ligand-independent mechanisms, involving the inhibition of 
aromatase (34). Aromatase is a critical enzyme in estrogen biosynthesis, and is 
upregulated in 70% of all breast cancers. Aromatase is highly correlated with 
cyclooxygenase 2 (COX-2), which is associated with the oncogene HER-2/neu (30). In 
T47D breast cancer cells, progesterone successfully antagonized these tumor-
promoting pathways by inhibiting the NFκB pathway.  
The breast cancer susceptibility gene BRCA1 is a tumor suppressor that 
interacts with and inhibits transcriptional activity of ER alpha (ERα) (35). Inherited 
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mutations in this gene confer a high risk for breast and ovarian cancers. Recent studies 
have even resulted in a commercially available test for the detection of an array of 
deletions and mutations in this gene (36; 37). Brca1-null and p53-deficient mice display 
extensive lateral branching and aveologenesis typical in pregnancy. Such findings led to 
a direct correlation between BRCA1 and PR action. BRCA1 inhibits the expression of 
various progesterone-responsive genes as well as progesterone-stimulated proliferation 
of T47D cells (35). Using c-myc as a model for a progesterone-regulated promoter, 
Katiyar and his colleagues showed that, although BRCA1 fails to block hormone 
binding, it works, in part, by preventing PR from binding to its PRE and then by 
recruiting a corepressor complex rather than a coactivator complex, inhibiting gene 
transcription (38). When mutated, this protein is unable to downregulate ER induction of 
the PR gene or PR activity, thus progesterone-dependent regulation of cell proliferation 
is hindered. However, the treatment of Brca1-null/p53-deficient mice with PR antagonist 
mifepristone (RU486) prevented mammary tumorigenesis (39). 
 
PROGESTERONE RECEPTOR MODULATORS 
Compounds with progesterone-inhibiting effects are quite useful in female 
reproductive health, including contraception and the prevention and treatment of 
progesterone-dependent diseases such as breast cancer and uterine leiomyomas. PR 
antagonists also serve as tools to dissect the many roles of PR, both in relation to the 
other steroid receptors and as an independent player in cells. Upon hormone binding to 
the receptor, PR binds as a dimer to its response element (PRE/GRE) on DNA, at which 
time co-regulators mediate recruitment of the coactivator complex and induce 
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transcription (3). Although the simplest way to antagonize PR action is by competing 
with hormone ligand for binding in the LBD, several steps in PR action may be 
amenable to control by antiprogestins. Small molecules (less than 1 kDa) could act by 
disassembling the HSP/chaperone complex, blocking DNA binding, altering tissue-
specific gene expression, recruiting corepressors instead of coactivators, or even 
modulating cell proliferation in tumors (8; 40). 
Based on in vitro characteristics, such as DNA binding and transcriptional 
behavior of the antagonist-occupied PR in the presence of protein kinase A activator, 
cyclic-AMP, three types of PR modulators have been defined (41; 42). Onapristine and 
other Type I antagonists, after binding to the receptor, prevent the conformational 
changes necessary for DNA binding, eliminating the possibility of the antiprogestin 
acting as a partial PR agonist. Type II antagonists allow binding of the receptor to the 
DNA and can display agonist activity upon PKA stimulation in vitro. Therefore, they 
exhibit partial PR agonist activity in a tissue- and species-specific manner. Mifepristone 
and asoprisnil are examples of Type II PR modulators. Type III PR antagonists, like 
ZK230211, resemble type II antagonists by inducing PR binding to its PRE, however, in 
diverse experimental settings, they display pure PR antagonistic activities without 
agonistic potential (43). 
Mifepristone (RU486) was the first PR antagonist developed, entering clinical 
trials in the early 1980s. Numerous studies have evaluated RU486 for pregnancy 
termination. Whether for expulsion of a fetus that underwent intrauteral death, ripening 
of the cervix for surgical abortion, or labor induction, the use of this drug in 
contraception has been widely explored. It has also been investigated as a treatment of 
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endometriosis and fibroids and as a first-line agent in treating metastatic breast cancers 
(7). RU486 actually binds to PR with a slightly higher affinity than progesterone, but fails 
to make the same contacts in the LBD as its agonist counterpart (44; 45). Although its 
direct mechanism of action is still unclear, it is postulated that after binding to the LBD, 
RU486 induces a conformation of the receptor that fails to induce the N-terminal and C-
terminal interaction between the AFs. The resulting DNA-bound receptor is rendered 
unproductive and is unable to recruit the co-regulators needed to activate gene 
transcription (8). 
Onapristone (ZK98299) was identified almost a decade after RU486, in the early 
1990s (46). It is a member of a series of 11β-aryl substituted antiprogestins. Unlike 
RU486, ZK98299 is a pure antagonist and was designed to exhibit lower anti-
glucocorticoid activity (41). This type I antagonist competes with progestins for binding 
at the LBD. It causes the receptor to adopt a conformation that does not promote the 
formation of a stable dimer, impairing PR binding to the PRE (47). Clinical trials of 
ZK98299 observed retardation of endometrial development and the impairment of 
gonadotropin release, blocking ovulation. Unfortunately, due to liver toxicity, further 
clinical development of this drug has been interrupted (48). 
Most other PR antagonists are not as extensively characterized as RU486 and 
ZK98299. Asoprisnil (J867), for example, was developed by Schering and TAP 
Pharmaceutical Products for treatment of progesterone-sensitive uterine fibroid tumors 
(49). In 2005, phase III trials were discontinued due to endometrial changes in patients. 
It is uncertain whether asoprisnil will be marketed, as studies with this compound are 
still underway in other contexts (6). Proellex (CDB4124) was another promising 
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antiprogestin that significantly decreased levels of the proliferation marker proliferating 
cell nuclear antigen (PCNA), anti-apoptotic protein Bcl-2, and viable leiomyoma smooth 
muscle cells. In addition, it increased levels of the apoptosis marker cleaved 
polyadenosine 5’-diphosphate-ribose polymerase (PARP) and the tumor suppressor 
Krüppel-like transcription factor 11 (KLF11). Clinical trials with CDB4124 have also 
recently been suspended due to increases in liver enzymes associated with drug use 
(50). 
An ideal PR antagonist would display potent receptor-specific inhibition, and 
hopefully tissue specificity. Its affects should be titrated and effective throughout the 
progressive stages of disease or tumor development. Most steroidal PR modulators are 
often associated with side effects due to cross-reactivity with other steroid receptors and 
metabolic pathways. Thus, nonsteroidal antagonists with higher receptor specificity are 
currently being pursued to improve biological responses and minimize side effects. 
 
 
 
 
 
 
 
 
 
 
	   13	  
 
 
 
 
Figure 1.1 The steroid hormone receptor family. All steroid receptors are composed of a 
variable N-terminal domain (A/B) containing the AF-1 transactivation region, a highly conserved 
DNA Binding Domain (DBD), a flexible hinge region (D), and a C-terminal Ligand Binding 
Domain (LBD, E) containing the AF-2 transactivation region. The upstream N-terminal region of 
PR-B contains AF-3, unique only to this isoform of the receptor. The estrogen receptor α is also 
unique in that it contains an additional C-terminal F domain. Numbers represent the length of 
the receptor in amino acids. PR, progesterone receptor; GR, glucocorticoid receptor; AR, 
androgen receptor; ER, estrogen receptor; MR, mineralocorticoid receptor. Adapted from 
Griekspoor et al., 2007 (3). 
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Figure 1.2 Nuclear transcription and extra-nuclear signaling pathways regulated by 
progesterone receptor. In the nuclear transcription pathway, agonist hormone ligand activates 
PR by inducing a conformational change that leads to nuclear translocation, dimerization, and 
binding to progesterone response elements (PREs) of target genes. Activated receptor bound to 
target DNA recruits coactivators that are essential for assembly of a productive transcription 
complex and for production of new RNA and protein that characterizes the cellular response to 
the hormone. PR can also associate in a hormone-dependent manner with cytoplasmic or cell 
membrane signaling molecules including the tyrosine kinase Src. This interaction leads to an 
activation of Src and the downstream Ras/raf/MAP kinase protein phosphorylation cascade. 
Adapted from Edwards, 2005 (51). 
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CHAPTER II: 
8-ALKYLTHIO-6-THIO-SUBSTITUTED THEOPHYLLINE ANALOGUES AS 
SELECTIVE NONCOMPETITIVE PROGESTERONE RECEPTOR ANTAGONISTS 
 
ABSTRACT 
The progesterone receptor (PR) plays a key role in reproduction and is important 
in cancers of the reproductive tract. Current PR antagonists usually compete for 
progestin binding in the PR ligand-binding pocket and often exhibit cross-binding with 
other members of the steroid receptor family. Using stably transfected cells expressing 
reporter genes, a set of ~150 theophylline analogues were screened for their ability to 
inhibit progesterone, estrogen, glucocorticoid and androgen signaling. The structure-
activity relationship studies presented here identify branched 8-alkylthio-6-thio-
substitutions of theophylline as selective PR inhibitors. 6-Thio-8-(2-
ethylbutyl)thiotheophylline (51), the most extensively studied derivative, does not act by 
competing with progestins for binding in the ligand-binding pocket of PR. It 
demonstrated the ability to inhibit the mouse mammary tumor virus (MMTV)-luciferase 
reporter and endogenous PR-regulated alkaline phosphatase activity in T47D breast 
cancer cells.  Compound 51 is the lead member of a novel class of PR inhibitors that act 
outside the PR ligand-binding pocket, thus serving as a novel probe to investigate PR 
action and a lead for further development.  
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INTRODUCTION 
Progesterone plays a key role in regulating ovulation, uterine contractility, and 
mammary tissue morphogenesis (1; 2). Most biological actions of progestins result from 
the activation of the progesterone receptor (PR), a ligand-dependent transcription factor 
(3). Hormone binding in the PR ligand-binding domain (LBD) induces a conformation 
that releases the heat shock protein complex, enabling PR to more efficiently enter the 
nucleus and bind as a homodimer to DNA response elements and regulate the 
transcription of target genes (4). 
Depending on the tissue, estrogens and progestins can work synergistically or 
antagonistically. While estrogen increases the levels of the two PR isoforms, PR-A and 
PR-B, progestins binding to PR can suppress estradiol-stimulated estrogen receptor 
alpha (ER) activity (5). PR antagonists have been developed as potential treatment 
options for progesterone-dependent gynecological disorders, such as endometriosis 
and uterine and breast cancers. In addition to their ability to inhibit the effects of 
endogenous progesterone, PR antagonists repress estrogen-dependent proliferation of 
the mammary gland and uterus (6; 7). Most antiprogestins, like mifepristone (RU486), 
are steroidal compounds that compete with progestins binding in the ligand-binding 
pocket of PR. Classical PR antagonists bind with high affinity and exhibit nanomolar 
potency, however, they often exhibit significant binding to the glucocorticoid receptor 
(GR) (8; 9). 
In a high-throughput screen, our laboratory identified a small molecule inhibitor of 
steroid receptor transactivation (10), 8-benzylsulfanylmethyl-1,3-dimethyl-3,7-dihydro-
purine-2,6-dione (TPBM), that belongs to a family of theophylline derivatives originally 
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synthesized by Dietz and Burgison (11; 12). A second small molecule characterized 
from this set, 8-((4-(4-fluorophenyl)-4-oxobutyl)thio)-1,3-dimethyl-6-thioxo-6,7-dihydro-
1H-purin-2(3H)-one (TPSF), showed increased potency and a different mode of action 
than TPBM (13). While TPBM acts in part by blocking receptor binding to response 
element DNA, TPSF increases the degradation of ligand-bound ER. These compounds 
demonstrate the diversity of action and specificity that this set of analogues present in 
modulating steroid receptor action. Structure activity relationship (SAR) studies identify 
correlations between changes in biological activity and molecular structure of a set of 
similar compounds. 
In the course of our SAR studies, we gained the unusual capacity to evaluate the 
activity of small molecules as inhibitors of transactivation mediated by four major steroid 
hormone receptors: ER, PR, GR, and androgen receptor (AR). In our evaluation of this 
set of structurally related theophylline derivatives, we identified 8-alkylthio-6-
thiotheophyllines that inhibited PR-mediated transactivation better than the parent 
compound theophylline. A subset of small molecules, having saturated carbon-chain 
branching, exhibited a clear preference for inhibiting PR relative to the other steroid 
receptors. Here, we describe a novel structural motif that exhibits receptor specificity 
and describe a small molecule inhibitor of PR that does not act by competing with 
progestins for binding to PR. 
 
EXPERIMENTAL PROCEDURES 
Chemistry 
Theophylline (1) was obtained from Sigma (St. Louis, MO). Compounds 2-55 
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were synthesized as described by Dietz and Burgison (11; 12), and obtained from the 
NCI Developmental Therapeutics Program. Solid compounds were dissolved in 
dimethyl sulfoxide (DMSO) and stored at -20°C. The lead compound, 6-thio-8-(2-
ethylbutyl)thiotheophylline (51), has 85% chemical purity as determined by LC/MS. 
 
Cell Culture 
Unless otherwise indicated, cells were maintained at 37°C in 5% CO2 in phenol 
red-free medium containing 1% penicillin/streptomycin and 10% fetal bovine serum 
(FBS) (Atlanta Biological, Atlanta, GA). T47D/A1-2 breast cancer cells, stably 
transfected to express additional GR and a mouse mammary tumor virus (MMTV)-
luciferase reporter (14), were maintained in minimum essential medium (MEM) 
supplemented with 10 mM HEPES, pH 7.4, 2 mM L-glutamine, and 0.2 mg/ml geneticin 
(G418). T47D-KBluc cells stably expressing an (ERE)3-luciferase reporter (15) were 
maintained in RPMI 1640 supplemented with 10 mM HEPES, pH 7.5, 2 mM l-glutamine, 
1.5 g/l sodium bicarbonate, 4.5 g/l glucose, and 1 mM sodium pyruvate. HeLa-AR1C-
PSA-Luc-A6 cells stably expressing AR and a prostate-specific antigen (PSA)-luciferase 
reporter (13) were maintained in MEM supplemented with 2 mM L-glutamine, 1 mM 
sodium pyruvate, 0.1 mg/ml hygromycin B (Roche Applied Science), and 0.5 mg/ml 
G418. T47D cells were maintained in phenol red MEM supplemented with 10 mM 
HEPES, pH 7.4, and 2 mM glutamine. MCF-7 breast cancer cells were maintained in 
MEM supplemented with 10 mM HEPES, pH 7.4, 2 mM glutamine, and 5% FBS. Four 
days before experiments, cells were transferred to the phenol red-free media described 
above, containing 10% dextran-charcoal treated (CD)-CS (T47D/A1-2 and HeLa cells) 
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or 10% CD-FBS (T47D-KBluc and T47D cells) with hormone or compound added in 
DMSO. MCF-7 cells were transferred to 5% CD-FBS and assays were conducted in 
10% CD-CS media. 
 
Reporter Gene Assays 
Assays for progesterone and glucocorticoid-dependent transactivation were 
performed in T47D/A1-2 breast cancer cells. Estrogen and androgen-dependent 
transactivations were assayed in T47D-KBluc and HeLa-A6 cells, respectively. Cells 
were seeded overnight and then treated with 5 nM of progesterone (P), dexamethasone 
(DEX), estradiol (E2), dihydrotestosterone (DHT), or ethanol vehicle, with or without 10 
µM of the test compounds in DMSO. After 24 h, cells were washed once with phosphate 
buffered saline (PBS) and lysed in passive lysis buffer (Promega, Madison WI). 
Luciferase activity was determined using BrightGlo firefly luciferase reagent from 
Promega. 
 
Alkaline Phosphatase Assay 
T47D cells were seeded overnight and then treated for 24 h with 2.5 nM P, with 
or without test compounds in DMSO. Cells were washed once with PBS, lysed in 
harvest buffer (20 mM potassium phosphate, pH 7.8, 5 mM MgCl2, 0.5% Triton X-100) 
and frozen at -70˚C. 5 µl of thawed supernatant was removed and assayed in a 96-well 
plate in 25 µl of assay buffer containing 100 mM diethanolamine, pH 9.5, 1 mM MgCl2, 
0.4 mM CSPD substrate (Applied Biosystems/Tropix) and 1X Emerald II enhancer 
(Applied Biosystems/Tropix). After 1 h at room temperature, luminescence was  
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measured in the visible spectrum (emission max. 542 nm). 
 
Enzyme Inhibition Assays 
Assays using purified luciferase protein and the test compounds were performed 
to rule out direct effects on luciferase enzyme activity. 0.05 ng of purified luciferase 
protein was added to 5 µl OneGlo Buffer (Promega) in a 96 well plate at a final 
concentration of 0.01 ng/µl luciferase protein. Each compound was diluted to 10 µM in 
buffer. 5 µl BrightGlo firefly luciferase reagent was added and incubated for 5 minutes 
before measuring luciferase activity. To test whether compounds directly affected 
alkaline phosphatase (AlkP) activity, lysates from cells treated with 2.5 nM P, to induce 
sufficient AlkP, were aliquoted and treated with 10 µM of each compound for 15 
minutes. Assay buffer (described above) was added to the lysate, incubated at room 
temperature for 1 h, and luminescence was measured. 
 
RNA Isolation and Quantitative PCR 
To induce alkaline phosphatase expression, cells were maintained in medium 
containing 10 nM P and the indicated concentrations of each compound in DMSO for 24 
h. Total RNA was isolated using the RNeasy Mini Kit (QIAGEN, Austin, TX) and 1 µg of 
RNA was reverse transcribed using ProtoScript M-MuLV First Strand cDNA Synthesis 
Kit (New England BioLabs, Ipswich, MA). Quantitative PCR was performed using Power 
SYBR Green PCR Master Mix (Applied Biosystems, United Kingdom). mRNA levels 
were measured by quantitative RT-PCR as described (13). Primers used in qRT-PCR 
were: AlkP, forward (5’-TCGCCTACCAGCTCATGCATAACA) and reverse (5’-
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TGAAGCTCTTCCAGGTGTCAACGA); pS2, forward (5’-ACCGGACACCTCAGACACG) 
and reverse (5’-CTGTGTTGTGAGCCGAGGC); and 36B4 internal standard, forward 
(5’-GTGTTCGACAATGGCACAT) and reverse (5’-GACACCCTCCAGGAAGCGA). 
 
Receptor Binding Assay 
Relative binding affinities were determined in a competitive radiometric assay as 
previously described (16–18) using 10 nM tritiated tracer, unlabeled promegestone 
(R5020) as standard, and 10 nM purified full length recombinant human PR-B (Pan 
Vera/Invitrogen, Carlsbad, CA). Incubations were for 18-24 h at 0°C. Hydroxyapatite 
(BioRad, Hercules, CA) was used to absorb receptor-ligand complexes, and free ligand 
was removed by washing with cold buffer. The data were analyzed using Prism 4.0. 
Binding affinities are expressed as relative binding affinity values with unlabeled R5020 
set to 100%. The 3H tracer, [17α-methyl-3H]-R5020 (Perkin-Elmer, Boston, MA), binds 
PR with a Kd of 0.4 nM. 
 
Statistical Analysis 
Results are expressed as mean ± standard error (SEM) of at least three 
independent experiments. Student's t-test was used for comparison of the means 
between two groups. Significance was established when p < 0.05. 
 
RESULTS 
The ability of 8-thioalkyltheophyllines to inhibit the activity of PR, ERα, GR and 
AR was assessed using stably transfected cell lines, each expressing receptor-specific 
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hormone response elements linked to a luciferase reporter. PR and GR activities were 
assayed in T47D/A1-2 breast cancer cells stably transfected to express a mammary 
tumor virus (MMTV)-luciferase promoter. ERα activity was assayed in T47D-KBluc cells 
expressing a reporter that contains 3 copies of the consensus estrogen response 
element (ERE)3-luciferase. AR activity was assayed in HeLa-A6 cells stably transfected 
to express AR and a prostate specific antigen (PSA)-luciferase reporter. Compounds 
were prepared as 10 mM stocks in DMSO and tested at 10 µM. The final DMSO 
concentration (0.1%) was below the 0.3% (v/v) concentration associated with cytotoxic 
effects (10). Receptor activity was assayed in the presence of progesterone (P) for PR, 
17β-estradiol (E2) for ER, dexamethasone (DEX) for GR, and dihydrotestosterone 
(DHT) for AR. Table 2.1 summarizes the percent transcriptional activity remaining in the 
presence of theophylline and 54 of its structural derivatives. Table 2.2 contains similar 
data for 93 more structurally diverse analogues of theophylline.  
Unmodified theophylline did not inhibit transactivation by any of the steroid 
receptors, whereas several theophylline derivatives exhibited varying levels of inhibition. 
To increase lipid solubility, oxygens in the X and Y positions were substituted with 
sulfurs. The resulting 8-alkylthio-2-thio, 8-alkylthio-6-thio, and 8-alkylthio-2,6-
dithiotheophyllines displayed increased inhibition of transactivation, with 6-thio-
substituted theophyllines being the most potent inhibitors. For example, compounds 24 
and 31 reduced steroid receptor activity to a greater extent than their unsubstituted, 2-
thio and 2,6-dithio counterparts (23-26 and 30-33, respectively). 
The 6-thiotheophyllines with 8-alkylthio-substitutions 5-9 carbons in length (24, 
31, and 34) inhibited PR activity 41-58%, but lacked specificity. Efficacy and specificity 
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for PR was improved with compounds with alkyl branching. For example, 45 and 46, 
with a single branched methyl group were moderately potent inhibitors of PR with no 
activity against ER, GR, and AR. Methyl branching on the terminal carbon improved 
efficacy, but also inhibited ER, as in the case of 48 and 49. Increasing the number of 
methyl groups with compound 49’s tertiary substitution inhibited PR activity 44%, but it 
also inhibited ER and GR. Compounds 51 and 52 had ethyl group side chains and 
inhibited PR to a greater extent than compounds with methyl side chains. The location 
of the ethyl side chain was also slightly more favorable in 51 and 52, which contain 
terminal branching. 
Based on the results of the primary screen that indicated IC50s <10 µM and 
specificity for PR, the alkyl-branched 8-alkylthio-6-thiotheophylline, compound 51, was 
selected as the lead compound for further study. Its structure is shown in Figure 2.1A. 
Since most current PR antagonists also inhibit GR, we assessed the potency and 
specificity of compound 51 in dose-response studies that compared its ability to inhibit 
PR, ER, GR, and AR (Figure 2.1B). In the luciferase reporter assays, 51 preferentially 
inhibited PR, followed by ER, AR, and then GR. Its IC50 was 2.3 µM for PR, which was 
2- to 6-fold lower than for the other receptors (Figure 2.1C). Since PR and GR activities 
were assessed in a single line of T47D cells, using the same MMTV-luciferase reporter, 
the absence of GR inhibition is not an artifact due to use of different cells and 
promoters. In these cells, compound 51 was a 6.1-fold more potent inhibitor of PR than 
GR, and compounds 48 and 52, which also contain this novel branched-chain alkyl 
motif, showed up to 10-fold increased potency on PR than GR (Figure 2.2). 
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We next tested the ability of the lead compound to inhibit progesterone induction 
of the endogenous alkaline phosphatase (AlkP) gene in T47D human breast cancer 
cells (19; 20). In these cells, AlkP enzyme activity was induced 23 fold by progesterone, 
but not by E2, DEX, or DHT (data not shown). 51 potently inhibited progesterone 
induction of AlkP activity with an IC50 of 1.2 µM and complete inhibition by 5 µM (Figure 
2.3A). 
We tested the possibility that the inhibition by 51 was an artifact due to direct 
inhibition of luciferase or alkaline phosphatase enzyme activity. Compound 51 did not 
inhibit the enzymatic activity of 0.05 ng of pure luciferase protein (t > 0.1). In lysates 
from cells in which progesterone was used to induce alkaline phosphatase activity (16.5 
± 0.3 fold induction relative to control), treatment with 51 failed to significantly inhibit 
activity (t > 0.3) (data not shown). 
The specificity study in Figure 2.1 used stably transfected reporter genes. To 
evaluate the effects of 51 on the expression of an endogenous gene, we used qRT-
PCR to investigate progesterone induction of alkaline phosphatase mRNA. The 11.8 ± 
1.6 fold induction in mRNA levels was inhibited 74% by 5 µM of compound 51, and 
completely blocked at 10 µM (Figure 2.3B). 
To compare 51’s ability to inhibit an ER-regulated endogenous gene, we 
analyzed pS2 mRNA. We tested the effect of compound 51 on ER at an early time, at 
which estrogen-ER has not yet induced PR, thus the cells were maintained in medium 
containing 5 µM compound 51 for only 2 hours. Under the same conditions in which 51 
completely blocked the progesterone induction of AlkP mRNA, it had no effect on the 
17β-estradiol induction of pS2 mRNA (Figure 2.4). As a positive control, the estrogen 
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antagonist, ICI 182,780 inhibited induction of pS2 mRNA. This data provides additional 
evidence that compound 51 preferentially inhibits PR-mediated gene expression. 
Most PR antagonists compete with progesterone for binding in the ligand-binding 
domain of the receptor. At functionally significant concentrations, compound 51 had little 
or no ability to compete with the radio-labeled synthetic progestin, promegestone 
(R5020), for binding to PR (Figure 2.5) and bound 4700-fold less well than R5020. 
These results indicate that 51 is unlikely to act by competing with progestins for binding 
in PR’s ligand-binding pocket. It remains possible that binding of 51, and other 
thiotheophylline derivatives, to a second site on PR triggers a conformational change 
that influences the ability of PR to bind progestins. 
 
DISCUSSION 
Previous studies showed that a set of 8-alkylthiotheophyllines displayed very 
weak antitumor activity (11). During a screen of a diversity test library, one of these 
compounds was identified as an inhibitor of ERα action (10). This set of small molecules 
was further explored to identify a structural motif that confers preferential inhibition of 
steroid hormone receptor activity. Replacing the oxygens in theophylline with sulfurs 
increased general inhibition of steroid receptor activity. 6-thio substitutions were more 
effective than 2-thio or 2,6-dithio substitutions. 8-thioalkyl substitution further increased 
potency, with preferential inhibition of PR as saturated chains 5-9 carbons in length 
were included. At shorter chain lengths, inhibition was generally weak, while longer 
chain lengths were not specific for inhibition of PR. Addition of saturated carbon-chain 
branching increased selectivity and potency for inhibiting PR activity. Our SAR 
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investigation of PR, ER, GR, and AR-responsive reporter genes identified compound 
51, which belongs to a set of saturated branched 8-alkylthio-6-thio-substituted 
theophyllines that preferentially inhibited PR. Compound 51 demonstrated pure 
antagonist effects – at concentrations of 30 µM and higher, there was no observed 
agonist activity or decrease in antagonism as is often seen with many selective PR 
modulators like RU486. 
The LBDs of steroid receptors share a similar structure with a moderately 
conserved amino acid sequence. Therefore, PR antagonists, like RU486 that binds in 
the ligand-binding pocket, tend to discriminate poorly between receptors. Their ability to 
exert anti-glucocorticoid activity limits the use of many PR antagonists. Our ability to 
identify small molecules that selectively inhibit PR over GR activity was enhanced by 
testing them on the same MMTV-luciferase reporter in T47D cells. Since the small 
molecules were assayed for inhibition of PR and GR on the same promoter in the same 
cells, it is highly unlikely that general toxicity is responsible for selective inhibition of PR 
by compound 51. 
  Ligand competition studies were used to evaluate the ability of 51 to compete 
with a progestin for binding to the ligand-binding pocket of PR. Based on these studies, 
compound 51 and other branched 8-alkylthio-6-thio-substitutions likely exert their 
actions outside the progestin binding pocket. 
Compound 51 inhibited PR-induced enzyme activity of the stably transfected 
luciferase reporter and endogenous alkaline phosphatase. Using quantitative RT-PCR, 
we also showed that 51 inhibits the progesterone-PR induction of AlkP mRNA. Thus, 
compound 51 is a noncompetitive inhibitor of PR-mediated gene expression. 
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PR, GR and AR are a subgroup of steroid receptors that can bind to the same 
DNA response element. How target genes are selectively activated by individual 
receptors is not well understood. Compound 51 may prove useful in elucidating 
differential effects of PR, GR and AR on gene expression and in distinguishing actions 
mediated by PR from those mediated by GR and other closely related members of the 
steroid receptor family. 
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Table 2.1 Inhibition of Steroid Receptor Activity by Theophylline Analogues 
 
 
 
    Reporter Assay (% Activity)a 
Cmpd X Y R PR ER GR AR 
1 O O H 105 93 91 95 
2 O O CH2CH3 76 106 120 83 
3 O O CH2CH2CH2CH3 155 88 121 80 
4 O O CH2Ph 144 94 117 102 
5 O O CH2CH2Ph 89 82 94 101 
6 O O SCH2CH3 60 98 100 115 
7 O O SCH2CH2CH3 89 111 101 108 
8 O O SCH2Ph 77 104 127 121 
9 O O SCH2CH2Ph 86 87 130 101 
10 O O SCH3 9 6 90 119 
11 O S SCH3 96 102 106 76 
12 S O SCH3 114 104 101 76 
13 S S SCH3 107 101 103 75 
14 O S SCH2CH3 89 83 112 80 
15 S O SCH2CH3 147 102 103 97 
16 S S SCH2CH3 123 95 102 86 
17 O S SCH2CH2CH3 104 75 116 95 
18 S O SCH2CH2CH3 202 82 82 104 
19 S S SCH2CH2CH3 64 79 79 78 
20 O S SCH2CH2CH2CH3 63 99 104 84 
21 S O SCH2CH2CH2CH3 117 87 82 150 
22 S S SCH2CH2CH2CH3 51 77 91 76 
23 O O SCH2CH2CH2CH2CH3 58 109 122 89 
24 O S SCH2CH2CH2CH2CH3 57 53 74 120 
25 S O SCH2CH2CH2CH2CH3 58 87 67 95 
26 S S SCH2CH2CH2CH2CH3 72 72 79 87 
27 S O SCH2CH2CH2CH2CH2CH3 76 91 78 85 
28 S S SCH2CH2CH2CH2CH2CH3 106 94 103 89 
29 S O SCH2CH2CH2CH2CH2CH2CH3 115 79 83 79 
30 O O SCH2CH2CH2CH2CH2CH2CH2CH3 33 112 92 101 
31 O S SCH2CH2CH2CH2CH2CH2CH2CH3 59 14 48 109 
32 S O SCH2CH2CH2CH2CH2CH2CH2CH3 82 79 91 81 
33 S S SCH2CH2CH2CH2CH2CH2CH2CH3 97 77 97 86 
34 O S SCH2CH2CH2CH2CH2CH2CH2CH2CH3 42 23 51 71 
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Table 2.1 (cont.) 
    Reporter Assay (% Activity) 
Cmpd X Y R PR ER GR AR 
35 S O SCH2CH2CH2CH2CH2CH2CH2CH2CH3 79 92 100 123 
36 S S SCH2CH2CH2CH2CH2CH2CH2CH2CH3 80 100 93 100 
37 O O SCH2CH2CH2CH2CH2CH2CH2CH2CH2CH3 72 109 88 107 
38 S O SCH2CH2CH2CH2CH2CH2CH2CH2CH2CH3 95 84 90 121 
39 S S SCH2CH2CH2CH2CH2CH2CH2CH2CH2CH3 66 96 85 85 
40 S O SCH2CH2CH2CH2CH2CH2CH2CH2CH2CH2CH3 73 105 95 91 
41 O S SCH2CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2CH3 76 49 98 104 
42 S O SCH2CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2CH3 87 112 97 91 
43 O S SCH2CH(CH3)2 67 93 80 134 
44 O S SCH(CH3)CH2CH3 86 85 86 103 
45 O S SCH(CH3)CH2CH2CH3 53 94 97 112 
46 O S SCH(CH3)CH2CH2CH2CH3 58 104 105 106 
47 O S SCH(CH3)CH2CH2CH2CH2CH2CH3 65 55 87 97 
48 O S SCH2CH2CH(CH3)2 35 65 89 74 
49 O S SCH2CH2C(CH3)3 56 45 83 90 
50 O S SCH(C2H5)CH2CH2CH3 51 72 71 78 
51 O S SCH2CH(C2H5)2 24 54 89 96 
52 O S SCH2CH(C2H5)CH2CH2CH2CH3 27 51 83 85 
53 O S SCH2Ph 58 86 156 97 
54 O S SCH2CH2Ph 15 33 78 114 
55 O S SCH2CH2CH2Ph 68 37 45 122 
 
aActivities were determined as a function (%) of maximal luciferase activity (100%) induced by 
hormone-bound steroid receptors (P:PR, E2:ER, DEX:GR, or DHT:AR) as described in the 
Experimental section.  
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Table 2.2 Inhibition of Steroid Receptor Activity by Compounds 56-148 
 
 
 
 
     Reporter Assay (% Activity)a 
Cmpd X Y R1 R2 PR ER GR AR 
56 O O CH2CH2CH3 H 92 117 105 83 
57 O O CH2CH2CH2CH3 CH3 94 96 85 84 
58 O O CH2CH2CH2CH2CH2CH3 H 118 56 137 108 
59 O O CH2CH2CH2CH2CH2CH2CH3 H 140 23 94 84 
60 O O CH(CH3)CH3 H 90 103 115 82 
61 O O CH(CH3)CH3 CH3 97 89 58 81 
62 O O CH(C2H5)CH2CH3 H 112 98 121 93 
63 O O CH2CH(CH3)2 H 91 105 80 74 
64 O O CH2CH2CH(CH3)2 H 152 77 144 114 
65 O O Ph H 193 51 157 134 
66 O O CH2Ph H 98 124 99 84 
67 O O CH2OPh H 131 85 198 91 
68 O O CH2SPh H 66 72 80 136 
69 O O CH2SCH2Ph H 75 70 89 84 
70 O O CHPh2 H 104 95 106 79 
71 O O C(Ph2)OH H 101 98 92 101 
72 O O CH(Ph)OCH3 H 89 107 107 93 
73 O O SCH2CH2CH2Ph H 67 74 122 93 
74 O O CH2Ph CH2CH2OH 149 88 83 97 
75 O O CH2Ph CH3 106 80 77 87 
76 O S SCH2CH2Ph CH2CH2Ph 35 59 120 73 
77 O O CH2CH=CH2 H 67 132 113 80 
78 O O CH2CH2CH2CO2H H 103 103 98 114 
79 O O CH2CH2CH2CH2CH2CO2H H 118 110 117 98 
80 O O CH2CH2CH2CH2CH2CH2CO2H H 109 107 107 70 
81 O O OCH(CH3)CH3 CH3 101 111 98 112 
82 O O CH2OCH3 H 101 95 76 105 
83 O O CH2OH H 109 103 112 93 
84 O O CH2CH2CH2OH H 98 115 89 108 
85 O O CH(OH)CH3 H 94 100 90 104 
86 O O CH(OH)CH3 CH3 107 90 96 110 
1-76, 78-148                                               77 
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Table 2.2 (cont.) 
     Reporter Assay (% Activity)a 
Cmpd X Y R1 R2 PR ER GR AR 
87 O O CH(OH)Ph CH3 104 65 111 85 
88 O O CH(SH)CH3 H 74 99 93 75 
89 O O CH2SH H 86 99 80 88 
90 O O CH2CH2SH H 69 86 67 86 
91 O O CH2SCH3 H 105 84 77 100 
92 O O CH2SC(CH3)3 H 72 98 81 101 
93 O O NHCH3 H 95 104 94 117 
94 O O CH2NH2 H 85 113 98 89 
95 O O CH2CH2NHCO2CH2CH3 H 92 99 84 103 
96 O O CH2CH2NHCO2CH2CH3 CH3 105 90 87 80 
97 O O CF2CF3 H 68 109 96 96 
98 O S =S H 84 109 110 81 
99 S O =S H 104 114 106 82 
100 S S =S H 99 98 92 71 
101 O S SCH2CH=CH2 H 104 70 80 82 
102 O S SCH2C(=O)CH3 H 105 102 92 109 
103 O S SCH2CH2N(CH3)2 H 58 87 91 93 
104 O S SCH2CH2N(C2H5)CH2CH3 H 89 106 105 130 
105 O S SCH2CH2NH2 H 74 127 99 104 
106 S O SCH2CH2NH2 H 115 128 86 97 
107 O O CH2-4-NHAcPh H 83 112 111 86 
108 O O CH2-4-NH2Ph H 92 90 119 88 
109 O O CH2-4-NH2Ph CH3 109 100 112 96 
110 O O CH2-4-(OCH2CH2N(C2H5)2)Ph H 112 116 107 95 
111 O O 2-pyridylethyl H 121 84 76 74 
112 O O 4-pyridylmethyl H 132 111 103 102 
113 O O 4-pyridylethyl H 114 96 126 104 
114 O O 2-pyridyl-CH=CH H 135 115 74 73 
115 O O 4-chloroPh H 112 75 97 89 
116 O O 2-methylPh H 74 79 48 89 
117 O O CH2-3-OHPh H 244 73 91 75 
118 O O CH2-4-OCH3Ph H 89 52 101 78 
119 O O CH2-4-OC2H5Ph H 40 30 39 75 
120 O O CH2-4-(OCH2Ph)Ph H 24 42 32 49 
121 O O CH2-3,4-dioxymethylPh H 88 105 96 93 
122 O O CH2-3,4-dioxyethylPh H 74 42 76 103 
123 O O SCH2-3,4-dimethylPh H 64 87 80 83 
124 O O 2-pyridyl-CH2S H 100 102 152 86 
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Table 2.2 (cont.) 
     Reporter Assay (% Activity)a 
Cmpd X Y R1 R2 PR ER GR AR 
125 O S 2-pyridyl-CH2S H 62 79 129 95 
126 S O 2-pyridyl-CH2S H 104 91 90 95 
127 O O 3-pyridyl-CH2S H 102 94 115 96 
128 O S 3-pyridyl-CH2S H 65 97 123 78 
129 S O 3-pyridyl-CH2S H 103 61 88 111 
130 O O 4-pyridyl-CH2S H 99 95 127 100 
131 O S 4-pyridyl-CH2S H 93 78 87 94 
132 S O 4-pyridyl-CH2S H 58 70 85 78 
133 O S 4-nitrophenyl-CH2S H 163 26 143 34 
134 O S S-cyclopentane H 82 84 84 112 
135 O O S-cyclohexane H 106 96 70 104 
136 O S S-cyclohexane H 102 76 86 108 
137 S O S-cyclohexane H 104 83 80 110 
138 O O CH2-cyclopentane H 116 100 81 96 
139 O O CH2-cyclohexene H 83 72 83 88 
140 O S 4-fluorobenzoylpropyl H 42 10 37 70 
141 O S 1-pyrrolidyl-CH2CH2S H 67 104 83 86 
142 O S 1-piperidyl-CH2CH2S H 88 85 104 120 
143 S O 1-piperidyl-CH2CH2S H 78 115 86 83 
144 O S 4-oxopiperidyl-CH2CH2S H 61 95 95 91 
145 O S N-ethyl-3-piperidyl-S H 52 100 97 93 
146 O S 2-tetrahydrofuryl-CH2S H 84 62 96 107 
147 O O methyl-2-thiophene H 121 103 78 77 
148 O O CH2-naphthalene H 85 54 169 105 
 
aActivities were determined as a function (%) of maximal luciferase activity (100%) induced by 
hormone-bound steroid receptors (P:PR, E2:ER, DEX:GR, or DHT:AR).  
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Figure 2.1 Compound 51 is a selective inhibitor of PR-mediated transactivation. (A) 
Structure of 51. (B) Inhibition of transactivation by 51 in reporter gene assays. Reporter assays 
were performed as described in the Experimental Procedures. For each hormone, activity in the 
absence of compound 51 was set as 100%. Error bars represent the SEM for at least three 
experiments. (C) IC50s were calculated using Sigma Plot 11.0.  
Receptor  IC50, µM 
PR  2.3 
ER  5.1 
GR  14.1 
AR  8.7 
                         (A) 
                                          
 
 
 
 
 
 
(B) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                               (C) 
 39 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2 Theophylline analogues containing branched alkylthio motif preferentially 
inhibit progesterone receptor activity. Reporter assays were performed as described in the 
Experimental Procedures for compounds 48 (A) and 52 (B). For each hormone, activity in the 
absence of compound was set as 100%. Error bars represent the SEM for at least three 
experiments. Structures of compounds are shown inset. 
(A) 
 
 
 
 
 
 
 
 
 
 
 
 
 
(B) 
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Figure 2.3. Compound 51 inhibits endogenous alkaline phosphatase. Inhibition of 
progesterone-induced alkaline phosphatase enzyme activity (A) and mRNA levels (B) in T47D 
cells. Alkaline phosphatase assays and qRT-PCR were performed as described in Experimental 
Procedures. Error bars represent the SEM for at least three experiments. AlkP activity in the 
absence of 51 was set to 100%. Enzyme activity IC50 = 1.2 µM. AlkP mRNA in the absence of 
hormone and 51 was set to 1.0. 
(A) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(B) 
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Figure 2.4. Comparison of inhibition of ER and PR-mediated gene expression by 
compound 51. (A) Estrogen-induced pS2 mRNA levels in MCF-7 breast cancer cells. (B) 
Progesterone-induced alkaline phosphatase mRNA in T47D cells. qRT-PCR assays were 
performed as described in the Experimental section. Cells were treated with 10 nM hormone 
(17β-estradiol:ER or progesterone:PR) and 5 µM of 51 or antiestrogen ICI 182, 780 (ICI) for 2 h. 
mRNA levels in the absence of hormone and compounds were set to 1.0. 
 
 
 
 
 
(A)           (B) 
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Figure 2.5. Competitive binding of compound 51 with 10 nM R5020 to the progesterone 
receptor. Competition assays were performed as described in the Experimental section. Error 
bars represent the SEM for at least three experiments. 
 
 
 
 
 
 
 
 
 
 
 
RBA = 0.021% 
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CHAPTER III: 
MECHANISM OF ACTION OF A NOVEL CLASS OF PROGESTERONE RECEPTOR 
MODULATORS - PR48, PR51, AND PR52 
 
ABSTRACT 
A screen of ~150 analogues of theophylline identified a structural motif that 
selectively inhibits progesterone receptor (PR) activity. PR48, PR51, and PR52 are 8-
alkylthio-6-thiotheophyllines with additional saturated carbon-chain branching that 
confers preference for PR over estrogen, glucocorticoid, and androgen receptors. 
These compounds have been shown to be noncompetitive inhibitors that act outside the 
ligand binding pocket of the receptor. They do not alter levels of PR in cells, nor do they 
directly inhibit luciferase, indicating these compounds are acting through the genomic 
actions of progesterone receptor. PR48, PR51, and PR52 all inhibit endogenous 
alkaline phosphatase (AlkP) activity in T47D cells, as well as PR-mediated induction of 
AlkP, sgk1, and E2F1 mRNA levels in a dose-dependent fashion. They possess the 
ability to completely antagonize progesterone-induced protein activity and mRNA levels. 
PR51 was selected as the representative lead compound for further testing due to its 
positive inhibition profile and purity. Although PR51 did not block PR binding to a 
consensus PRE probe in an in vitro fluorescence polarization assay, chromatin 
immunoprecipitation in T47D cells showed that it blocked PR binding to the PRE in the 
enhancer region of sgk1. Moreover, when nuclear and cytoplasmic extracts were 
isolated and probed for PR content, PR51 promoted cytoplasmic retention of PR and 
decreased nuclear localization. We propose that this novel class of PR-selective small 
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molecule inhibitors acts in part by reducing the nuclear accumulation of progestin-bound 
PR in cells. These novel selective noncompetitive inhibitors of PR-mediated gene 
transcription represent a new class of pure antagonists. 
 
INTRODUCTION 
Progesterone, a key player in reproductive development, has become a target for 
the development of antihormone agents (1; 2). Progesterone works through the 
progesterone receptor (PR), a member of the steroid hormone receptor family of 
transcription factors. This hormone and other progestins bind to the C-terminal ligand 
binding domain (LBD) of the receptor (3; 4). The resulting conformational change in the 
receptor induces a set of actions that lead to the up or downregulation of gene 
transcription. The ligand-bound receptor dissociates from heat shock protein complex, 
promoting nuclear localization, where it binds as a homodimer to progesterone-
responsive elements (PREs) on DNA. Depending on the target gene and conformation 
of the bound receptor, it recruits coactivators to upregulate, or corepressors to 
downregulate, transcription (5). Once the high affinity binding of hormones to their 
receptors was better understood, antihormones became a primary focus for controlling 
steroid receptor action. 
Analogues of progesterone have been developed for use as oral contraceptives. 
The oldest compound, mifepristone (RU486), (6–8) contains substitutions at the 11β 
and 17α positions that are characteristic of this and other steroidal antagonists (9). They 
are effective in blocking PR-mediated follicular development and ovulation, but show 
unwanted side effects throughout the reproductive process. They also demonstrate 
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varying levels of cross-reactivity between other steroid receptors, most notably the 
glucocorticoid receptor (GR) (10; 11). 
PR is specifically required for pregnancy-associated ductal proliferation and 
lobuloalveolar differentiation of the mammary epithelium (12). Ablation of PR expression 
in mouse studies resulted in a significantly reduced incidence of mammary tumor 
growth in response to carcinogens (13). Such observations implicate a specific role for 
PR, distinct from ER, as a mediator for the initiation of mammary tumorigenesis. In post-
menopausal breast cancer patients who have been on hormone replacement regimens, 
more aggressive tumors and increased likelihood of metastasis are correlated with 
replenishing progesterone in their systems (14; 15). Because PR is a useful prognostic 
marker for breast cancer survival, selective antagonists of the receptor have emerged 
as promising therapeutics (16). 
The role of PR in mammary tumorigenesis stems from its involvement in 
proliferation, as it works in concert with a host of cell cycle checkpoint genes and tumor 
suppressors, including, but certainly not limited to cyclin D1, bcl-2, p53, and BRCA1 
(17–19). BRCA1 is a tumor suppressor protein that, when it contains certain point 
mutations, gives rise to a hereditary form of breast cancer (20–22). These mutations 
impair its ability to downregulate PR-mediated cell proliferation. Mice given a regimen of 
RU486 had fewer tumors as adults, whereas control mice developed tumors. This is just 
one example of the application of antiprogestins. 
Most classical PR antagonists are steroidal antiprogestins that can be placed in 
one of three categories (23–25). Type I antagonists act by blocking PR binding to its 
DNA response elements. Type II and III antagonists allow PR to bind to DNA, but 
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induce conformational changes that alter gene transcription. Whereas type II 
antagonists may exert partial antagonism in dose and tissue-dependent settings, type III 
antagonists are classified as pure antagonists. Our lab has recently identified a set of 
structurally similar small molecule inhibitors of PR action. Although this novel set of 
compounds appear to behave like type I PR-selective antagonists, they are non-
steroidal and inhibit PR activity by binding outside of the ligand binding pocket of the 
receptor.  
 
EXPERIMENTAL PROCEDURES 
Cell Culture 
Unless otherwise indicated, cells were maintained at 37°C in 5% CO2 in phenol 
red-free medium containing 1% penicillin/streptomycin and 10% fetal bovine serum 
(FBS) (Atlanta Biological, Atlanta, GA). T47D/A1-2 breast cancer cells, stably 
transfected to express additional GR and a mouse mammary tumor virus (MMTV)-
luciferase reporter (26), were maintained in minimum essential medium (MEM) 
supplemented with 10 mM HEPES, pH 7.4, 2 mM L-glutamine, and 0.2 mg/ml geneticin 
(G418). T47D-KBluc cells stably expressing an (ERE)3-luciferase reporter (27) were 
maintained in RPMI 1640 supplemented with 10 mM HEPES, pH 7.5, 2 mM l-glutamine, 
1.5 g/l sodium bicarbonate, 4.5 g/l glucose, and 1 mM sodium pyruvate. HeLa-AR1C-
PSA-Luc-A6 cells stably expressing AR and a prostate-specific antigen (PSA)-luciferase 
reporter were maintained in MEM supplemented with 2 mM L-glutamine, 1 mM sodium 
pyruvate, 0.1 mg/ml hygromycin B (Roche Applied Science, Germany), and 0.5 mg/ml 
G418. T47D cells were maintained in phenol red MEM supplemented with 10 mM 
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HEPES, pH 7.4, and 2 mM glutamine. MCF-7 breast cancer cells were maintained in 
MEM supplemented with 10 mM HEPES, pH 7.4, 2 mM glutamine, and 5% FBS. Four 
days before experiments, cells were transferred to the phenol red-free media described 
above, containing 10% dextran-charcoal treated (CD)-CS (T47D/A1-2 and HeLa cells) 
or 10% CD-FBS (T47D-KBluc and T47D cells) with hormone or compound added in 
DMSO. PR- and ER-negative MDA-MB-231 human breast cancer cells were maintained 
in phenol red-free MEM supplemented with 10 mM HEPES, pH 7.4, 2 mM glutamine, 
and 10% FBS. Experiments with these cells were conducted using the same growth 
medium above. 
 
Reporter Gene Assays 
Reporter gene assays were performed to compare the ability of about ~150 
compounds structurally related to theophylline (28) to inhibit progesterone and 
glucocorticoid-dependent transcription in T47D/A1-2 breast cancer cells stably 
transfected to express GR and an MMTV-Luc reporter. The ability of compounds to 
inhibit ER and AR transcriptional activity was assayed in T47D-KBluc breast cancer 
cells stably transfected to express an (ERE)3-Luc reporter and in HeLa AR1C-PSA-Luc-
A6 cells that stably express human AR and a PSA-Luc reporter. Four days before each 
experiment, cells were switched to medium containing CD-treated serum as described 
above. T47DA/1-2 and T47D-KBluc cells (200,000 cells/well) and HeLa AR-PSA-Luc 
cells (100,000 cells/well) were plated in 1 ml of media in 24-well plates. After 24 h, 5 nM 
of hormone – P4, DEX, E2, DHT, or DMSO vehicle - with or without 10 µM compound 
were added to each well. After 24 h, cells were washed once with phosphate-buffered 
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saline and lysed in 100 µl of passive lysis buffer (Promega, Madison WI). Luciferase 
activity was determined using BrightGlo firefly luciferase reagent from Promega.  
 
Cell Proliferation Assay 
ER and PR-negative MDA-MB-231 human breast cancer cell lines were provided 
by Prof. A. Nardulli. The cells were maintained and assayed in phenol red-free minimal 
essential medium with 10% FBS and antibiotics. To assay anchorage-dependent cell 
growth, 1000 cells/well were plated in a 96-well plate. After 24 h, the medium was 
changed to include progesterone, compounds, or 0.1% (v/v) DMSO vehicle. The 
medium was not changed during the assay. After 3 days, cell viability was determined 
using the Promega CellTiter 96® Aqueous One Solution Cell Proliferation Assay (MTS) 
(Promega). 
  
Western Blot 
T47D cells were plated at 300,000 cells/well in 6-well plates in MEM containing 
10% CD-FBS. Cells were treated with 5 nM P4 and 10 µM compounds in 0.3% (v/v) 
DMSO. Whole cell extracts were prepared after 24 h in 1x radioimmune precipitation 
assay (RIPA) buffer (Millipore, CA) containing protease inhibitor mixture (Roche Applied 
Science). Extract (20 µg of total protein) was run on 7.5% SDS-PAGE gels and 
transferred to nitrocellulose membranes. Membrane was probed using a 1:5000 dilution 
of PR monoclonal antibody PgR1294 (gift from Dean Edwards, Baylor College of 
Medicine) (29) and 1:10,000 dilution of β-actin monoclonal antibody (Sigma). 
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Densitometry analysis was performed using PhosphorImager and Image Quant 5.0 
software. 
 
Fluorescence Anisotropy Assay 
The fluorescence anisotropy microplate assay for analyzing binding of PR-B to 
the fluorescein-labeled consensus PRE/GRE was as described (28). Full-length human 
FLAG-PR-B was purified as described (30). A 30-bp oligonucleotide containing the 
cPRE/GRE was synthesized with fluorescein at its 5’-end using phosphoramidite 
chemistry and PolyPak II (Glen Research Corp, Sterling, VA) purified by the 
Biotechnology Center (University of Illinois, Urbana, IL). This flcPRE was used in our 
earlier work describing FAMA (31; 32). The sequence of the fluorescein-labeled sense 
strand, with the cPRE half sites underlined, is: 5’-fl-CTAGATTACAGAACAATCTGTTCT 
TACTCA-3’. After column purification, double-stranded probes were produced by 
annealing the fluorescein-labeled sense strand with an equimolar amount (both at 1µM) 
of the unlabeled antisense strand oligonucleotide in TE buffer (10 mM Tris, pH 7.5, 1 
mM EDTA) containing 100 mM NaCl at 100°C for 5 min, followed by slow cooling in a 
water bath to form double-stranded probe. 
Assays were carried out at room temperature in black wall 96-well microplates 
(Greiner/Bio-One) in a total volume of 20 µl in buffer containing 20 mM Tris, pH 7.5, 
10% glycerol, 0.2 mM EDTA, 2 mM dithiothreitol, 100 mM KCl, 0.5 ng/µl poly(dI:dC), 
250 ng/µl bovine serum albumin, 100 nM P4, and 1 nM flcPRE probe. Purified hPR-B 
(final concentration 10 nM) and small molecules (≤ 5% (v/v)) were pre-incubated in 96-
well plate for 5 min. Assay buffer (described above) was added to wells and mixed 
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without creating bubbles. The plate was briefly centrifuged and incubated at room 
temperature for 10 min, and fluorescence anisotropy was measured using a BMG 
PheraStar (BMG Labtech) microplate reader (module: FP 485 520 520) with excitation 
at 485 nm and emission at 520 nm. To identify if small molecules were highly 
fluorescent or quenched fluorescence, fluorescence intensity was also measured. 
 
RNA Isolation and Quantitative PCR 
Wild type T47D cells were maintained for 4 days in medium containing 5% 1x 
CD-CS. Cells were treated with 10nM P4 and varied concentrations of compound in 
DMSO for 24 h. Total RNA was isolated using the RNeasy Mini Kit (QIAGEN, Austin, 
TX) and one microgram was reverse transcribed using ProtoScript M-MuLV First Strand 
cDNA Synthesis Kit (New England BioLabs, Ipswich, MA). qPCRs were performed with 
Power SYBR Green PCR Master Mix (Applied Biosystems, United Kingdom). mRNA 
levels were measured by quantitative RT-PCR as described (33). Primers used in qRT-
PCR were: SGK1, forward (5′-GGTTCTTCTAGCAAGACACAAGG) and reverse (5′-
GCTCCGACATAATATGCTTCTCC); E2F1, forward (5′-ACGTGACGTGTCAGGACCT) 
and reverse (5′-GATCGGGCCTTGTTTGCTCT); and 36B4 internal standard, forward 
(5′-GTGTTCGACAATGGCAGCAT) and reverse (5′-GACACCCTCCAGGAAGCGA). 
 
Chromatin Immunoprecipitation 
T47D cells were treated with compound and/or hormone for 1 h. DNA-protein 
complexes were cross-linked with 1% formaldehyde for 10 min. The cells were washed 
in ice-cold PBS containing protease inhibitors and lysed by the addition of MC lysis 
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buffer (10 mM Tris-HCl, pH 7.5, 10 mM NaCl, 3 mM MgCl2, and 0.5% NP-40). Lysates 
were digested with micrococcal nuclease and sonicated on ice for five cycles, with each 
cycle consisting of 15 sec of pulsing followed by a 20-sec cooling interval, using a Sonic 
Dismembrator 100 (Fisher Scientific, St. Louis, MO). DNA fragments were isolated via 
centrifugation and diluted 5-fold with ChIP dilution buffer (16.7 mM Tris-HCl, pH 8, 167 
mM NaCl, 1.2 mM EDTA, and 1.1% Triton X-100). Preclearing was done overnight at 
4˚C by the addition of Protein A/G Agarose (50% slurry, GE Healthcare) and continuous 
rocking.  
Immunoprecipitations were performed by incubating the diluted chromatin lysate 
with either antibody for PR (5 µg monoclonal PgR1294), RNA Polymerase II (2 µg, 
Millipore), or normal mouse IgG (1 µg, Millipore) overnight at 4˚C, followed by a 1-h 
incubation with protein A/G beads. Beads were washed 3 times with low salt buffer 
(0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl, pH 8, and 150 mM NaCl), 
once with high salt buffer (the same, except with 500 mM NaCl), once with LiCl wash 
buffer (0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM Tris-HCl, pH 8, and 
250 mM LiCl), and twice with TE (10 mM Tris-HCl, pH 8, and 1 mM EDTA). 
Immunoprecipitated histones were eluted in 5% SDS and 0.5 M NaHCO3. Protein-DNA 
complexes were reverse cross-linked overnight with 5M NaCl, followed by treatment 
with RNase A (Millipore) and incubation with proteinase K. DNA was purified using 
DNeasy® Blood & Tissue Kit (QIAGEN, TX) according to the manufacturer’s protocol. 
Purified DNA was subjected to qPCR amplification of a sequence spanning the 
PRE within the sgk1 gene promoter (nucleotides –1175 to –1189) using Power SYBR 
Green PCR Master Mix. The primer pairs used in qPCR were: SGK1, forward (5’-
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CTTGTTACCTCCTCACGTG) and reverse (5’-GTCGTCTCTGCACTAAGG); and 
GAPDH forward (5’-TACTAGCGGTTTTACGGGCG) and reverse (5’-TCGAACAGGAG 
GAGCAGAGAGCGA). 
 
Nuclear Localization 
T47D cells were plated at a density of 2 x 106 cells/well in a 100mm plate 
(Falcon) containing 10% CD-FBS. Cells were treated with 10 nM P4 with or without 10 
µM PR51 in 0.1% (v/v) DMSO. Cellular extracts were prepared using a Nuclear Extract 
Kit (Active Motif, CA) and the manufacturer’s protocol. All steps were performed at 4°C. 
Treatment media was removed after 1 h and the cell monolayer washed with 5 ml ice-
cold PBS containing phosphatase inhibitors. The wash solution was discarded and 3 ml 
of fresh PBS was added. Cells were scraped off the plate into the buffer and cell pellet 
was collected after centrifugation for 5 min at 500 rpm. 
To prepare the cytoplasmic fraction, the cell pellet was resuspended and 
incubated in 1X Hypotonic Buffer to complete cell membrane lysis. Detergent was 
added and the suspension was centrifuged at 14,000 x g for 30 sec. The resulting 
supernatant (cytoplasmic fraction) was collected and stored at -80°C. The pellet was 
resuspended and incubated in Complete Lysis Buffer (containing 1 mM DTT) while 
rocking on ice for 30 min. The mixture was centrifuged at 14,000 x g for 10 min and the 
supernatant (nuclear fraction) was collected and stored at -80°C. Fractions were 
analyzed by Western blot according to the Experimental Procedures above. The 
proteins markers were α-tubulin (antibody from Sigma) for the cytosol fraction and lamin 
(antibody A/C (636) from Santa Cruz) for the nuclear fraction. 
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RESULTS 
Structural Motif Selectively Inhibits PR and Binds Outside Ligand Binding Pocket 
We evaluated the ability of ~150 compounds structurally related to theophylline to 
inhibit steroid receptor activity in cells containing stably transfected hormone-responsive 
reporters. Progesterone:PR and dexamethasone (DEX):GR-mediated activity were 
assayed in T47D/A1-2 human breast cancer cells, containing MMTV-luciferase (26). 
Estradiol (E2):ER activity was assayed using an (ERE)3-Luc reporter in T47D-KBluc 
cells (27) and Dihydrotestosterone:androgen receptor (DHT:AR) activity was assayed 
using a PSA-Luc reporter in HeLa-AR1C-PSA-Luc-A6 cells (28). Initial screening 
compared the ability of 10 µM of each small molecule to inhibit receptor activity at 
saturating hormone levels (5 nM) in each cell line. Of the compounds tested, PR48, 
PR51, and PR52 (“Lead Compounds”) inhibited PR activity at least 2-fold better than 
ER and up to 10-fold better than GR (Table 3.1). These compounds all belong to a set 
of 8-alkylthio-6-thiotheophyllines with additional saturated carbon chain branching on 
the 8-substituted alkyl group that help to confer its specificity for PR. Upon testing their 
inhibitory effects on endogenous alkaline phosphatase, these compounds are slightly 
more potent inhibitors than on the MMTV-luciferase reporter and were similar in their 
effectiveness as inhibitors.  
 If the lead compounds acted by competing with hormone binding in the ligand 
binding pocket of the receptor, they would be successfully displaced by increasing the 
hormone concentration to supersaturating levels. Radiolabeled synthetic progestin, 
R5020, was used to test the binding affinity of the small molecules. PR48, PR51, and 
PR52 all failed to bind receptor in their working concentration range. Compared to 10 
	   56	  
nM R5020, their relative binding affinities for PR were 0.012%, 0.021%, and 0.501%, 
respectively. RBAs were calculated from dose curves for the compounds ranging from 
10-11 to 10-4 M (Table 3.2). 
 
Compounds are Predicted to Have Favorable Druglikeness 
Our lead compounds were scored for their druglikeness to compare their 
structural characteristics to that of progesterone, antagonist RU486, and their base 
compound theophylline, which are all commercially available drugs (Table 3.3). We 
followed a model that incorporated Lipinski’s Rule of 5, considering molecular weight, 
solubility, hydrophilicity, and fragment-based druglikeness (34; 35). This analysis is 
solely computational and only used as a predictive measure to gauge potential 
pharmacological properties of a compound.  
The first factor considered was molecular weight (MW).  According to the 
Comprehensive Medicinal Chemistry (CMC) database (36), the qualifying range 
(covering 80% of pharmaceuticals) for a potential drug is between 160 and 480 g/mol. 
Smaller molecular weights allow for better diffusion into cells. Our lead compounds had 
MWs comparable to progesterone and the synthetic progestin R5020 (298-340), which 
are all under the CMC average of 357, whereas RU486 was on the higher end with 429. 
Since a compound is transported in aqueous media like blood and intracellular 
fluid, is must have sufficient water solubility. In the absolute sense, lower water solubility 
translates to slow absorption and activity. For our calculations, molar solubility (logS) 
should be greater than -5.0. Our lead compounds all possessed solubilities greater than 
the steroidal progestins (-2.96 to -3.77 compared to -4.36 and -4.51, respectively). Even 
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 though RU486 is a widely used drug, it has poor predictive solubility (-7.15). 
In addition to being aqueous soluble, an optimal drug must also be soluble to fat 
because, if orally administered, it must pass through the intestinal lining and penetrate 
the lipid membrane to enter the cell. The model compound for the cellular membrane is 
octanol, so the logarithm of a compound’s partition coefficient between n-octanol and 
water (cLogP) is used to determine its hydrophilicity (37). Low hydrophilicity, that is high 
cLogP, tends to cause poor absorption or permeation. A reasonable value would be 
less than 5.0. PR52 is just shy of this upper limit (4.79), along with R5020 (4.73). The 
other lead compounds and progesterone have cLogP values less than 4.0. Again, 
RU486 exceeds the upper limit for optimality (5.92), yet has survived clinical trials. 
Overall drug likeness was scored using a fragmentation-based method. A 
complete list of ~5300 distinct substructure fragments was created by shredding 3300 
traded drugs as well as 15,000 commercially available chemicals (Fluka) to yield a list of 
all available fragments. A positive value indicates that a compound predominantly 
contains fragments which are frequently present in commercial drugs, but the qualifying 
range is between -2.0 and 5. PR48 and PR51 have drug likeness scores between that 
of progestin and R5020, but PR52’s was -3.85. This is possibly due to the saturated 
alkyl branching that would computationally appear unfavorable toward predicting 
absorption and action. However, we believe that this structural characteristic is actually 
a primary source of its ability to specifically inhibit PR-mediated genomic activity.  
 
The Compounds Exhibit Low Toxicity in PR-negative MDA-MB-231 Cells 
Because our screen was cell-based, we assumed that the small molecules that 
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passed the primary screen could enter the cells. Although each compound was tested in 
3 different cell lines, we wanted to verify that they were not exerting nonspecific toxic 
effects. To test for general cell toxicity, the PR-negative and ER-negative MDA-MB-231 
cell line was used (Figure 3.1). Cells were maintained in 10% FBS and treated with 
compounds for 3 days. Viability was measured using the MTS assay as described in 
Experimental Procedures. Treatment with 10 nM progesterone was used to verify that 
these PR-negative breast cancer cells are non-responsive to progestins. Growth of the 
MDA-MB-231 cells was unaffected by 2.5 µM of the compounds, but was reduced by 
22% with 10 µM PR48. PR52 inhibited cell growth 38% and PR51 up to 60% at this 
concentration. Most cell growth was blocked at 30 µM, but a higher concentration of 
DMSO was used to treat the cells. Although toxic effects of these compounds were 
observed between 10 and 30 µM, these compounds exhibited their PR-specific 
inhibition at 4-10 times lower concentrations. It may even be considered that the 
inhibition of the receptors at the higher concentrations is not hormone-responsive but 
due to general toxicity in the cells. All three lead compounds reached maximum efficacy 
on PR-mediated luciferase and endogenous alkaline phosphatase activities by 5 µM 
(See Table 3.1.), which is below any toxicity-inducing concentration observed in the 
MDA-MB-231 cells.  
 
The Compounds Do Not Alter Progesterone Downregulation of PR Levels 
Through competitive binding assays, using the radiolabeled progestin R5020, we 
showed that our compounds were extremely weak binders, and certainly not effective 
competitors with progestins for binding in the ligand binding pocket of the receptor 
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(Table 3.2). We considered the idea that they were affecting PR prior to its activity as a 
transcription regulator. The compounds could be affecting the pathway for production, 
stabilization, or degradation of the receptor. T47D cells were treated with 10 µM of each 
compound with or without progesterone for 20 h. Figure 3.2 shows that the progestin-
stimulated downregulation of PR-B (120 kDa) levels (38) was unaffected by the addition 
of our compounds. Since our compounds do not appear to affect the levels of receptor 
or ligand binding, yet inhibited PR-mediated protein activity, we looked at the 
intermediary steps of PR action between ligand binding and transcription activation. 
 
The Compounds Do Not Block PR Binding to the PRE In Vitro 
 A major step in PR acting as a transcription factor is its ability to bind to a 
response element on DNA. Our lab developed a fluorescence anisotropy microplate 
assay (FAMA) that allows us to quantify PR binding to the progesterone response 
element (PRE) in vitro (31; 32). When polarized light excites a fluorophore, which in this 
instance is a fluorescein-labeled consensus PRE (flcPRE), the relatively small flcPRE 
undergoes rotational diffusion more rapidly than the time required for light emission. 
Therefore, the position of the flcPRE at the time of light emission is largely randomized, 
resulting in depolarization of most of the emitted light. Fluorescence anisotropy (FA) 
values are derived from measurements of fluorescence intensity in the parallel (II) and 
perpendicular (=) directions. FA = [(Intensityll) - (Intensity=)] / [(Intensityll) + 2(Intensity=)]. 
When full-length PR binds to the flcPRE, the larger size of the flcPRE:PR complex 
causes the rotation to be slower, thus the emitted light remains highly polarized. 
Receptor-DNA interaction is therefore observed as a change in FA, and interference of 
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flcPRE:PR binding by a potential PR antagonist will reduce this change in FA. The 
FA/FP assay is performed in solution and provides true equilibrium analysis and real-
time kinetic data. 
 In this in vitro assay to test small molecule inhibition of PR binding to the PRE, at 
20 µM, all 3 compounds failed to block DNA binding (Figure 3.3). TPBM is another 
derivative of theophylline that selectively inhibits ERα (and PR at high concentrations) 
(28). TPBM’s structure does not contain the 6-thio group and has different 8-alkylthio 
substitutions from our lead compounds. It inhibits receptor activity by blocking binding to 
its DNA response element, as seen in FAMA and with chromatin immunoprecipitation. 
We used this compound in our assay as a positive control. RU486, as mentioned 
earlier, is a type II PR antagonist and did not block DNA binding in this assay. Because 
our compounds fail to block DNA binding, but inhibit PR-mediated gene expression, we 
next looked at their ability to inhibit expression of endogenous progesterone-PR induced 
mRNAs. 
 
Compounds Inhibit Progesterone-induced Gene Expression in T47D Cells 
To determine the site in PR’s genomic actions that our inhibitors specifically 
target, we explored the small molecules’ effects on progesterone-responsive genes 
(Figure 3.4). Serum- and glucocorticoid regulated kinase 1 (SGK1) is a gene that 
encodes a serine/threonine protein kinase and is involved in epithelial ion transport and 
cell survival responses (39; 40). It contains a well-characterized PRE/GRE (41). E2F1 is 
another progestin-regulated gene that has been confirmed by microarray and qPCR 
data in multiple labs (5; 42; 43). The E2F family of transcription factors regulates the 
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expression of genes involved in cell cycle progression, DNA synthesis and repair, and 
tumor suppressor protein action. 
mRNAs were induced with 10 nM progesterone for 24 h in T47D cells. Sgk1 was 
induced ~45 fold and this induction was abolished by the addition of 30 µM of the lead 
compounds. PR48 inhibited expression 50% at 10 µM, whereas PR51 and PR52 
exhibited ~90% or greater inhibition at this concentration. A similar trend in efficacy 
between the 3 compounds was observed for the inhibition of E2F1 mRNA expression. 
Only 30% inhibition was observed with 30 µM PR48. In contrast, PR51 and PR52 
inhibited expression 60% and 50%, respectively, with 5 µM treatment and >90% at 10 
µM. Our lead compounds showed a dose-dependent inhibition of progestin-induced 
endogenous mRNA expression in T47D cells, thus indicating that these small molecules 
inhibit PR-mediated gene expression. 
 
PR51 Inhibits PR Binding to the PRE of a Progesterone-Regulated Gene 
 Although the lead compounds did not block PR binding to a consensus PRE 
probe in the in vitro fluorescence polarization assay, it was important to evaluate its 
effect in intact cells. The cellular environment contains a host of factors that contribute 
to receptor-DNA binding that are not present in an in vitro assay using purified PR and 
deproteinized DNA. Although the small molecules may not act by directly blocking PR 
binding, they may have a more indirect action that could produce the same result. 
Chromatin immunoprecipitation (ChIP) was performed to observe the recruitment 
of PR to the PRE in the enhancer region of sgk1 (Figure 3.5). 100 nM P4 stimulated an 
100-fold increase in site occupancy that was blocked ~90% by 10 µM PR51. This was 
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confirmed by a comparable inhibition of RNA polymerase II recruitment. The 17-fold 
increase in site occupancy by RNA polymerase II was reduced to 2.6 fold with the 
addition of inhibitor. These findings suggest that the small molecules act prior to DNA 
binding, but post-ligand binding. 
 
PR51 Affects the Cellular Localization of Agonist-bound PR 
 A simple explanation for the reduction in PR-DNA binding, and subsequent gene 
transcription, would be that there is either less global receptor in the cells or that the 
receptor is unable to localize to its target DNA sites. Western blot analysis showed that 
these small molecules had no significant affect on PR levels in T47D cells, so we 
examined the cellular localization of PR after treatment with progesterone and our 
inhibitors. Unliganded progesterone receptor maintains a cellular distribution between 
the cytoplasm and nucleus that is shifted toward nuclear accumulation upon progestin 
binding. This new distribution promotes activation of PR-mediated transcription. Nuclear 
and cytoplasmic fractions were isolated from T47D cells 1 h after treatment with 10 nM 
progesterone, with or without 10 µM PR51. Hormone treatment caused a 60% reduction 
in cytoplasmic PR and a corresponding 2.9 fold increase in PR localized in the nucleus 
(Figure 3.6). The addition of PR51 blocked the nuclear localization of liganded PR. 
Inhibition of the nuclear accumulation of liganded PR following treatment with PR51 
may be a primary factor that contributes to the ability of PR51 to inhibit PR-mediated 
gene expression. 
 
 
	   63	  
DISCUSSION 
 An optimal small molecule inhibitor of progesterone:PR action would exhibit 
specificity for PR and low nonspecific toxicity. From a targeted screen of theophylline 
analogues, we identified a set of structurally similar small molecules (<1 kDa) that 
possess a structural motif that preferentially inhibits PR activity within the steroid 
receptor family of transcription factors. PR48, PR51, and PR52 are 8-alkylthio-6-
thiotheophyllines that contain additional saturated alkyl branching on the 8-subsituted 
group. These compounds exhibit 2-10 fold higher potency for inhibiting PR-mediated 
reporter activity. Although their IC50s are higher than most PR antagonists (2-3 µM), 
they exert their effects by acting outside the ligand binding pocket of the receptor. 
Because they are noncompetitive inhibitors, their higher effective concentration is not as 
great of a hindrance to their action. This also serves as an advantage for continued use 
when cells, particular tumors, exhibit hormone-independent receptor activity.  
 
Druglikeness of Small Molecule Inhibitors 
There is a set of computational approaches to predict the likelihood that a 
compound can become a useful and effective drug. We used some components of 
Lipinski’s Rule of Five methodology to analyze our lead compounds for their 
druglikeness. All of the compounds possessed favorable molecular weights under 500, 
predicting favorable diffusion across membranes and therefore, increasing access to 
their cytosol receptor target. Our compounds also calculated molar solubilities greater 
than 4.0, which are better than the progestins and clinically-used antiprogestin RU486. 
Lipid and water solubility must be balanced to achieve optimal transport through the 
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body, and our group of compounds scored below the upper limit (cLogP < 5.0), ranging 
between that of progesterone and RU486. PR48 and PR51 had overall druglikeness 
scores that were favorable. This value was based on scoring all the unique fragments of 
~20,000 commercially developed drugs. PR52 was given a highly negative score, even 
though RU486 was also negative. A positive druglikeness states that a compound 
contains fragments which are frequently present in commercial drugs. This, however, 
does not denote balance concerning other properties. A molecule may be composed of 
multiple drug-like but lipophilic fragments, receiving a high druglikeness score, yet 
adverse cLogP. It is important to note that these measures are all predictive and not 
absolute because there are many dynamic factors in the cell environment that can both 
hinder and enhance drug activity. We believe that the saturated alkyl branching is the 
structural moiety responsible for the negative druglikeness score. Although this is an 
uncommon motif in drugs, it is likely the unique quality that distinguishes this group of 
nonsteroidal selective PR antagonists. 
 
Target Site of Inhibition in PR Genomic Action 
 The initial cell-based screen of the 150 analogues of theophylline measured the 
activity of luciferase that was induced by hormone receptor-responsive reporters. 
Through the use of pure proteins and cell extract, we verified that our compounds were 
not acting directly on the functional protein, but through PR-mediated activity. At the 
working concentrations of each of the lead compounds, they exhibited minimal general 
toxicity. Western blots of PR levels excluded the possibility that our compounds were 
inhibiting PR production or stability. In T47D cells, they failed to downregulate the levels  
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of PR in the presence and absence of progesterone. 
 From competitive binding assays, we know that our compounds do not compete 
with progestins for binding at the concentrations with which they exert their inhibitory 
effects on PR-mediated gene transactivation. They also successfully reduced progestin-
PR-induction of the endogenous genes sgk1 and E2F1 in T47D cells. We then used a 
fluorescence anisotropy assay developed in our lab to observe real-time kinetics of PR 
binding to the PRE. The lead compounds all failed to block PR:PRE binding, whereas 
TPBM, a control theophylline analogue quite different from our compounds, was able to 
block binding at high concentrations. 
 Interestingly, ChIP in T47D cells, showed that the PR51 inhibited binding of PR 
to the PRE in the sgk1 gene. PR51 greatly reduced occupancy of progesterone receptor 
and RNA polymerase at the sgk1 promoter. There are factors within the cellular 
environment that are not present in the in vitro FAMA, which uses purified PR-B and 
DNA probe. The small molecules did not appear to directly disrupt PR dimerization or 
the receptor-DNA interface, which are observable in the fluorescence anisotropy assay. 
We explored the effect of PR51 on the intracellular localization of PR. Compared to 
treatment with hormone alone, treatment of T47D cells with PR51 greatly reduced the 
nuclear accumulation of PR. This altered localization of PR is likely a significant cause 
of the reduced nuclear action of the receptor. Thus, PR51 and its set of alkyl-branched 
8-alkylthio-6-thiotheophyllines present a novel mechanism for preferentially inhibiting 
PR action. Their limited cross-reactivity and noncompetitive inhibition of PR make them 
useful tools for elucidating the role of PR, particularly without ER, in reproduction and 
cancers. 
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Table 3.1 Structures of PR48, PR51, and PR52 and Relative Potencies for 
Inhibiting Steroid Receptor Activity 
 
 
 PR48     PR51    PR52 
  Luciferase Reporter Assay  
  IC50, µM  Relative Potency  
Compound  PR  ER  GR  AR  
Alkaline Phosphatase 
Assay Relative Potency 
PR48  3.3  4.1  9.7  6.6  0.79 
PR51  2.3  2.2  6.1  3.8  0.65 
PR52  2.3  2.1  7.2  3.5  0.78 
 
IC50s for each compound were calculated using Sigma Plot 12.0 from dose-response curves 
(0.5-30 µM) of inhibition of hormone-responsive reporter and endogenous gene activities. 
Relative potency is based on the IC50 value of each compound inhibiting PR-induced reporter 
activity in T47D/A1-2 cells. DEX:GR activity was assayed in the same cells, E2:ER in T47D-
KBluc cells, and DHT:AR in HeLa-A6 cells. Endogenous alkaline phosphatase activity was 
assayed in T47D cells. Data is the mean of at least 3 independent experiments for each 
concentration on the dose curve. 
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Table 3.2 Competitive Binding of Compounds Lead Compounds to the 
Progesterone Receptor 
 
Compound  IC50 (µM)  RBA (%)  R2 
R5020  0.01438  100  0.9878 
PR48  124.3  0.012  0.8933 
PR51  69.51  0.021  0.6211 
PR52  2.870  0.501  0.4199 
 
IC50 values were determined from dose-response curves ranging from 10-11 to 10-4 M. R2 values 
are low because complete curves had to be interpolated from data. Data was analyzed with 
Prism 4.0. 
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Table 3.3 Predicted Druglikeness of Progesterone Receptor Modulators 
 
 Progesterone   R5020     RU486 
Compound 
 Molecular 
Weight (g/mol) 
 Molar Solubility 
(logS) 
 Hydrophilicity 
(cLogP) 
 
Drug Likeness 
Progesterone  299  -4.36  3.69  0.59 
R5020  326  -4.51  4.73  2.44 
RU486  429  -7.15  5.92  -0.82 
Theophylline  180  -1.48  -0.09  1.09 
PR48  298  -2.96  3.40  0.68 
PR51  312  -3.23  3.86  1.27 
PR52  340  -3.77  4.79  -3.85 
 
Parameters are scored based on Lipinski’s Rule of Five (34). 
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Figure 3.1 Effect of small molecules on cell proliferation in PR-negative breast cancer 
cells. PR and ER-negative MDA-MB-231 cells were maintained in medium containing no 
hormone. The cells were maintained for 3 days in the indicated concentrations of small 
molecules or progesterone, and viability was assayed as described using the MTS assay. The 
data represent the mean ± SEM for at least six replicates at each concentration. 
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Figure 3.2 Western blot analysis of PR levels in T47D cells. T47D cells were treated with 10 
µM of PR48, PR51, or PR52 with or without 5 nM P4 for 20 h. Cells were harvested and total 
cell extract was prepared according to Experimental Procedures. PR-B (120 kDa) was detected 
using monoclonal antibody PgR1294. 
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Figure 3.3 Small molecule inhibition of PR binding to flcPRE. FAMA was carried out in 96-
well black wall microplates as described in Experimental Procedures. Samples contained 10 nM 
purified full length human PR-B, fluorescein-labeled consensus PRE/GRE oligonucleotide 
probe, 100 nM P4, and the indicated concentrations of small molecules. 10 nM PR-B is enough 
receptor to saturate 80% of the flcPRE in solution. Anisotropy change is the increase in 
anisotropy observed after P4:PR binds to the flcPRE. Data represent the mean ± SEM for four 
independent experiments. 
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Figure 3.4 Effect of small molecule inhibitors on PR-mediated gene expression in T47D 
cells. Cells were maintained for 24 h in medium containing 10 nM P4, with or without 
compounds (at the indicated concentrations). RNA was isolated and (A) sgk1 and (B) E2F1 
mRNA levels were measured using quantitative PCR as described in Experimental Procedures. 
Data represent the mean ± SEM for at least four independent experiments at each 
concentration. 
(A) 
 
 
 
 
 
 
 
 
 
 
 
 (B) 
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Figure 3.5 Chromatin immunoprecipitation shows PR51 inhibits binding of PR to the PRE 
in sgk1. T47D cells were treated with 100 nM P4 with or without 10 µM PR51 for 1 h. ChIP was 
performed as described in Experimental Procedures with antibodies against PR (PgR1294, 
empty bars), RNA polymerase II (gray bars), and Normal mouse IgG (control, black bars). qPCR 
analysis was done using primers spanning the PRE-containing region in the enhancer of sgk1. 
Data are presented as the mean percent input ± SEM for triplicate amplification reactions from 
one representative experiment. 
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Figure 3.6 Effect of PR51 on the nuclear localization of PR. T47D cells were treated with 10 
nM P4 with or without 10 µM PR51 for 1 h. Cells were harvested and cytoplasmic (empty bars) 
and nuclear (filled bars) fractions were collected and assayed by western blot as described in 
Experimental Procedures. Relative levels of PR (120 kDa) were calculated by PhosphorImager 
quantitation of band intensity and normalized to α-tubulin (50 kDa) or lamin C (63 kDa). 
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CHAPTER IV: 
SELECTIVE PR ANTAGONIST TPFY CAN BE USED TO DISTINGUISH 
PROGESTERONE AND GLUCOCORTICOID GENE REGULATION 
 
ABSTRACT 
Efforts to use progesterone receptor (PR) modulators for the treatment of 
reproductive disorders and cancer are growing. Currently, their most common use is for 
contraception. Since the development of the first antiprogestin RU486 30 years ago, all 
antiprogestins demonstrate some cross-reactivity with the other steroid receptors, 
especially glucocorticoid receptor (GR). PR and GR have highly homologous DNA 
binding domains and bind the same response element on DNA, the PRE/GRE. The 
mechanism by which these 2 receptors selectively regulate the same and different 
target genes is not fully understood. We have characterized a small molecule that 
selectively inhibits PR activity with no significant anti-glucocorticoid activity. 8-(Fluoren-
9-yl)-theophylline, or TPFY, is a nonsteroidal PR antagonist that binds outside the 
ligand binding pocket of the receptor. It inhibits PR-mediated reporter and endogenous 
gene activity with low micromolar potency and does not block PR binding to the PRE in 
vitro. Our studies suggest that TPFY acts through inhibiting the genomic activities of 
PR. Since TPFY has no anti-glucocorticoid activity, it can serve as a useful tool to 
elucidate differences in PR and GR-mediated gene regulation. 
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INTRODUCTION 
Within the nuclear receptor superfamily of transcription factors, there is a 
subfamily of steroid receptors (1). Members of this group include progesterone 
receptors (PR), estrogen receptors (ER), androgen receptors (AR), glucocorticoid 
receptors (GR) and mineralocorticoid receptors (MR). They all contain 3 major domains: 
an N-terminal domain (NTD) and a DNA binding domain (DBD) that is connected to the 
C-terminal ligand binding domain (LBD) by a short flexible hinge region (2) (Figure 1.1). 
The most conserved domain between members of this subfamily is the DBD. PR and 
GR share 90% amino acid sequence homology in this region, more than any other two 
steroid receptors. Their LBD’s are 55% homologous, and the most variable region 
between the two receptors and throughout the family is the NTD, with less than 15% 
similarity. 
 A unique characteristic of this family is the ability of multiple receptors to bind to 
similar response elements on DNA. PR and GR bind the same consensus sequence, 
the PRE/GRE. In the future, it will be referred to as the PRE. Still quite poorly 
understood is how and why different cell responses are observed for androgen, 
glucocorticoid, mineralocorticoid, and progestins, even though each receptor-steroid 
complex can bind to very similar, or identical, DNA sequences to regulate gene 
transcription (3; 4). Some cellular systems are designed to select one hormone over 
another. In MR-responsive tissues, the receptor is co-localized with 11β-hydroxysteroid 
dehydrogenase type 2 (11β-HSD2). This enzyme converts cortisol to inactive cortisone, 
protecting MR from overstimulation by glucocorticoids. Recent studies have also found 
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that varying levels of individual receptors, coactivators, and corepressors can alter the 
efficacy of agonist ligand-bound complexes (5). 
 Cross-reactivity is a major concern in the development of PR antagonists, 
especially when it involves anti-glucocorticoid activity. RU486 is a steroidal antiprogestin 
that binds to the PR with high affinity and inhibits it with great potency, but is also blocks 
GR activity very effectively (6; 7). As a result, the side effects of continued long-term 
usage are a concern (8). 
Although current antiprogestins bind to the GR, there have been many attempts 
to modify RU486 in hopes of reducing its anti-glucocorticoid activity (9–11). Onapristone 
(ZK98299), which contains a 13α-configured retro steroid, has a lower GR binding 
affinity than RU486 (12). However, this compound also has a reduced affinity for PR. 
One of the most important modifications in the steroid skeleton of antiprogestins that 
influences their ability to bind to GR seems to be substitutions at position C-17 (6). Org. 
33628 contains an acetophenone group at C-11 and a methylene-furan substitution at 
C-17. These substitutions not only result in 25-fold lower binding to GR compared with 
RU486, but also a 2-fold higher affinity for PR than RU486 (13). More recently 
described is ZK230211, which has a 17β-pentafluorethyl side chain at position C-17. 
This steroidal antiprogestin was found to have a markedly reduced anti-glucocorticoid 
activity compared to RU486 when assessed in vivo for the ability to reverse thymus 
involution (14). 
 An “active antagonist” approach has been explored that does not involve finding 
a compound that will not bind GR, but rather attempts to identify compounds with 
different mechanisms of action on PR and GR. RTI-012 and RTI-022 were two such 
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compounds that failed to promote GR translocation and binding to DNA, but did 
promote these interactions with PR (15). Because the concentration required for “active 
antagonism” of PR was much lower than that for “competitive antagonism” of GR, a 
functional separation of steroid receptor antagonism was achieved. Combining this 
mechanism-based approach to functionally selecting for PR inhibition with traditional 
direct binding approaches, it may be possible to develop antiprogestins that are specific 
for PR with minimal activity on GR.  
Our laboratory’s screens focus on targeting nonsteroidal small molecule 
inhibitors of PR, few of which have been well characterized in the past. An LG-series of 
PR antagonists, that were 6-aryl-1,2-dihydro-2,2,4-trimethylquinolines, exhibited 
potencies comparable or equal to ZK98299, but were unsuccessful in limiting cross-
reactivity with GR and AR (16; 17). Tetrahydropyridazines are another class of 
nonsteroidal compounds that have shown antiprogestin activity. Although they showed 
no affinity for AR, ER, and GR at concentrations of up to 10 µM, they demonstrated only 
modest binding affinities to PR (18). One of the lead compounds, RWJ26329, displayed 
mixed agonist and antagonist activity. 
A nonsteroidal pure antagonist that combines the mechanism-based selectivity 
for PR inhibition would serve as a useful tool in elucidating PR and GR activities. 
 
EXPERIMENTAL PROCEDURES 
Cell Culture 
Unless otherwise indicated, cells were maintained at 37°C in 5% CO2 in phenol 
red-free growth medium containing 1% penicillin and streptomycin and fetal bovine 
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serum (FBS) (Atlanta Biological, Atlanta, GA) or calf serum (CS). T47D/A1-2 breast 
cancer cells that stably express the glucocorticoid receptor (GR) and contain a mouse 
mammary tumor virus (MMTV)-luciferase reporter (19) were maintained in MEM 
supplemented with 10 mM HEPES, pH 7.4, 2 mM glutamine, 5% FBS, and 0.2 mg/ml 
Geneticin (G418). T47D-KBluc cells expressing an (ERE)3-luciferase reporter gene (20) 
were maintained in RPMI 1640, containing 2 mM l-glutamine, 1.5 g/liter sodium 
bicarbonate, 4.5 g/liter glucose, 10 mM HEPES, pH 7.5, 1 mM sodium pyruvate, and 
10% FBS. HeLa-AR1C-PSA-Luc-A6 cells that stably express androgen receptor (AR) 
and a prostate-specific antigen (PSA)-Luc reporter were maintained in MEM 
supplemented with 2 mM l-glutamine, 1 mM sodium pyruvate, 10% FBS under selection 
with 0.1 mg/ml hygromycin B (Roche Applied Science), and 0.5 mg/ml G418. Wild type 
T47D cells were maintained in phenol red MEM supplemented with 10 mM HEPES, pH 
7.4, 2 mM glutamine, and 10% FBS. Four days before experiments, cells were 
transferred to the indicated phenol red-free medium, containing 10% 2x charcoal 
dextran treated calf serum (CD-CS) (T47D/A1-2 and HeLa) or 10% CD-FBS (T47D-
KBluc and T47D) and hormone (in ethanol) or compound (in DMSO). PR- and ER-
negative MDA-MB-231 human breast cancer cells were maintained in phenol red-free 
MEM supplemented with 10 mM HEPES, pH 7.4, 2 mM glutamine, and 10% FBS. 
Experiments with these cells were conducted using the same growth medium above. 
 
Reporter Gene Assays 
Reporter gene assays were performed to compare the ability of TPFY to inhibit 
PR, GR, ER, and AR-dependent transactivation. PR and GR were assayed in T47D/A1-
	   85	  
2 breast cancer cells, and ER and AR transcriptional activity was assayed in T47D-
KBluc cells and HeLa AR1C-PSA-Luc-A6 cells, respectively. Four days before each 
experiment, cells were switched to medium containing CD-treated serum as described 
above. T47DA/1-2 and T47D-KBluc cells (200,000 cells/well) and HeLa-A6 cells 
(100,000 cells/well) were plated in 1 ml of media in 24-well plates overnight. Hormone 
(5 nM P4, 2.5 nM DEX, 200 pM E2, 80 pM DHT) or ethanol vehicle, with or without 
TPFY (5, 10, 20, 30, or 50 µM) was added to each well. After 24 h, cells were washed 
once with phosphate-buffered saline and lysed in 100 µl of passive lysis buffer 
(Promega, Madison WI). Luciferase activity was determined using BrightGlo firefly 
luciferase reagent from Promega.  
 
Alkaline Phosphatase Assays 
T47D cells were maintained in 10% CD-FBS phenol red-free medium for 4 days 
before experiment. Cells were seeded 10,000 cells/well in 100 µl of medium in 96-well 
plates. After 24 h, progesterone (2.5 or 500 nM) was added with or without TPFY (0.5, 
1, 2.5, 5, 10, or 30 µM) in DMSO. After another 24 h, cells were washed once with PBS, 
lysed in 100 µl of buffer (20 mM potassium phosphate, pH 7.8, 5 mM MgCl2, 0.5% 
Triton X-100) and frozen at -70˚C. 5 µl of thawed supernatant was removed and 
assayed in a 96-well plate in 25 µl of assay buffer (100 mM diethanolamine, pH 9.5, 1 
mM MgCl2, 0.4 mM CSPD substrate (Applied Biosystems/Tropix) and 1x Emerald II 
enhancer (Applied Biosystems/Tropix)). After 1 h at room temperature, luminescence in 
the visible spectrum (emission max. 542 nm) was read for 1 sec. 
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Protein Inhibition Assays 
 An assay using purified luciferase protein and TPFY was performed eliminate the 
possibility that the small molecule was directly acting on the luciferase protein and not 
acting through PR. 0.05 ng of purified luciferase protein was added to 5 µl OneGlo 
Buffer (Promega) in a 96-well plate, making a total concentration of 0.01 ng/µl luciferase 
protein. TPFY was diluted into the buffer for an active concentration of 10 µM. 5 µl 
BrightGlo firefly luciferase reagent was added and incubated for 5 minutes before 
reading luciferase activity. 
 To test whether TPFY was acting directly on alkaline phosphatase, lysate from 
cells treated with 2.5 nM P4 was aliquoted and treated with 10 µM TPFY for 15 minutes. 
Assay buffer (described above) was added to lysate, incubated at room temperature for 
1 h, and measured for luminescence. 
 
RNA Isolation and Quantitative PCR 
Wild type T47D cells were maintained for 4 days in medium containing 10% CD-
FBS. To induce alkaline phosphatase expression, cells were maintained in medium 
containing 10 nM P4 and TPFY (5, 10, or 30 µM) in DMSO for 24 h. Total RNA was 
isolated using the RNeasy Mini Kit (QIAGEN, TX) and one microgram was reverse 
transcribed using ProtoScript M-MuLV First Strand cDNA Synthesis Kit (New England 
BioLabs, MA). Quantitative PCRs were performed with Power SYBR Green PCR 
Master Mix (Applied Biosystems, United Kingdom). mRNA levels were measured as 
previously described(21). Primers used in qRT-PCR were: AlkP, forward (5′-TCGCCT 
ACCAGCTCATGCATAACA) and reverse (5′-TGAAGCTCTTCCAGGTGTCAACGA); 
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and 36B4 internal standard, forward (5′-GTGTTCGACAATGGCAGCAT) and reverse 
(5′-GACACCCTCCAGGAAGCGA). 
 
Western Blots 
T47D cells were plated at 300,000 cells/well in 6-well plates in MEM containing 
10% CD-FBS. Cells were treated with 2.5 nM P4 and 5 µM TPFY in 0.3% (v/v) DMSO. 
Whole cell extracts were prepared after 20-24 h in 1x radioimmune precipitation assay 
(RIPA) buffer (Millipore, CA) containing protease inhibitor mixture (Roche Applied 
Science). Extract (20 µg of protein/lane) was run on 7.5% SDS-PAGE gels and 
transferred to nitrocellulose membranes. PR was detected using a 1:1000 dilution of PR 
monoclonal antibody Ab-8 (NeoMarkers, Freemont, CA). The blot was stripped for 30 
min and reprobed using a 1:10,000 dilution of β-actin monoclonal antibody (Sigma). For 
detecting alkaline phosphatase levels, cells were treated with 10 µM TPFY and protein 
was run on a 10% TGX gel (BioRad). Tissue nonspecific alkaline phosphatase (TNAP) 
was probed using monoclonal antibody Alkaline Phosphatase F-4 (Santa Cruz), diluted 
1:1000. Densitometry analysis was performed using PhosphorImager and Image Quant 
5.0 software. 
 
Cell Proliferation Assays 
To assay anchorage-dependent cell growth, T47D cells were maintained in 
phenol red-free minimal essential medium with 10% CD-FBS and antibiotics for 3 days 
before hormone induction. 1000 cells/well were plated in a 96-well plate, and after 24 h, 
the medium was changed to include 10 nM P4 and 10 µM TPFY (or DMSO vehicle). 
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The medium was not changed during the experiment, and after 4 days, cell viability was 
determined using Promega CellTiter 96® Aqueous One Solution Cell Proliferation Assay 
(MTS) (Promega). Cell numbers were calculated from a standard curve of absorbance 
(490nm - 650nm) versus serially diluted cells on Day 0. General toxicity was tested 
using ER and PR-negative MDA-MB-231 human breast cancer cell lines. The cells were 
maintained and assayed in phenol red-free minimal essential medium with 10% FBS 
and antibiotics. 1000 cells/well were plated in a 96-well plate. After 24 h, the medium 
was changed to include 10 nM P4, TPFY (2.5, 10, or 30 µM) or DMSO vehicle. The 
medium was not changed during assay. After 3 days, cell viability was determined using 
Promega CellTiter 96® Aqueous One Solution Cell Proliferation Assay (MTS) 
(Promega). 
  
Fluorescence Anisotropy Assay 
The fluorescence anisotropy microplate assay for analyzing binding of PR-B to 
the fluorescein-labeled consensus PRE/GRE was performed as described (22). Assays 
were carried out at room temperature in black wall 96-well microplates (Greiner/Bio-
One) in a total volume of 20 µl in buffer containing 20 mM Tris, pH 7.5, 10% glycerol, 
0.2 mM EDTA, 2 mM dithiothreitol, 100 mM KCl, 0.5 ng/µl poly(dI:dC), 250 ng/µl bovine 
serum albumin, 100 nM P4, and 1 nM flcPRE probe. The sequence of the fluorescein-
labeled sense strand, with the cPRE half sites underlined, is: 5’-fl-CTAGATTACAGA 
ACAATCTGTTCTTACTCA-3’. Purified hPR-B (final concentration 10 nM) and TPFY (≤ 
5% (v/v)) were pre-incubated in 96-well plate for 5 minutes. Assay buffer (described 
above) was added to wells and mixed without creating bubbles. The plate was briefly 
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centrifuged, incubated for 10 min, and measured for fluorescence anisotropy using a 
BMG PheraStar (BMG Labtech) microplate reader (module: FP 485 520 520) with 
excitation at 485 nm and emission at 520 nm. 
 
Nuclear Localization 
T47D cells were plated at a density of 2 x 106 cells/well in a 100mm plate 
(Falcon) containing 10% CD-FBS. Cells were treated with 10 nM P4 with or without 10 
µM TPFY in 0.1% (v/v) DMSO. Cellular extracts were prepared using a Nuclear Extract 
Kit (Active Motif, CA) and the manufacturer’s protocol. All steps were performed at 4°C. 
Treatment media was removed after 1 h and the cell monolayer washed with 5 ml ice-
cold PBS containing phosphatase inhibitors. The wash solution was discarded and 3 ml 
of fresh PBS was added. Cells were scraped off the plate into the buffer and cell pellet 
was collected after centrifugation for 5 min at 500 rpm. 
To prepare the cytoplasmic fraction, the cell pellet was resuspended and 
incubated in 1X hypotonic buffer to complete cell membrane lysis. Detergent was added 
and the suspension was centrifuged at 14,000 x g for 30 sec. The resulting supernatant 
(cytoplasmic fraction) was collected and stored at -80°C. The pellet was resuspended 
and incubated in Complete Lysis Buffer (containing 1 mM DTT) while rocking on ice for 
30 min. The mixture was centrifuged at 14,000 x g for 10 min and the supernatant 
(nuclear fraction) was collected and stored at -80°C. Fractions were analyzed by 
western blot according to the Experimental Procedures above. 
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RESULTS 
A Nonsteroidal Small Molecule Exhibits Specificity for Inhibiting PR-Mediated Reporter 
Activity 
 Our laboratory had previously conducted an in vitro screen to identify small 
molecule inhibitors of steroid hormone receptor action that block receptors binding to 
their hormone response elements. One such compound, TPBM, was identified for 
inhibiting ERα action (22). TPBM is one of a panel of 200 derivatives of theophylline 
synthesized to test their anticancer activity and ability to modulate central nervous 
system activity (23). When assaying these compounds for their ability to selectively 
inhibit PR activity over other steroid receptors, specifically GR, ER, and AR, one 
compound that showed great potential was 8-(fluoren-9-yl)-theophylline, or TPFY 
(Figure 4.1, inset). Dose response curves against the 4 receptors on stably transfected 
luciferase reporters showed that TPFY inhibited over 80% of PR activity at 30 µM, 
whereas it did not pass a threshold of 30% inhibition on any of the other receptors 
(Figure 4.1). ER was assayed at concentrations up to 50 µM (data not shown) and its 
IC50 was ~ 61 µM. The IC50 for PR activity was 8.0 µM. For AR and GR, there was too 
little inhibition to determine an IC50. IC50s were calculated using Sigma Plot. 
TPFY’s low anti-glucocorticoid activity made this a promising compound and led 
us to pursue its mechanism of action. The PR and GR assays were conducted in the 
same T47D/A1-2 breast cancer cells. Both receptors bind mouse mammary tumor virus 
(MMTV) promoter and can activate transcription of the luciferase reporter. Since the 
assays were done in the same cells, effects due to cell context and environmental 
differences are eliminated.  
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TPFY Inhibits Endogenous Gene Activity and Does Not Compete for Ligand Binding 
 To test whether TPFY could also inhibit an endogenous gene, we assayed 
alkaline phosphatase activity in T47D cells (Figure 4.2). Progesterone has been shown 
in this cell line to stimulate de novo synthesis of a form of tissue nonspecific alkaline 
phosphatase (TNAP) (24; 25). Although GR can also induce transcription of this protein, 
it requires micromolar concentrations, allowing us to assess PR-specific stimulation of 
the gene with the nanomolar hormone concentrations we use in our assays. Using a 
chemiluminescent assay to measure alkaline phosphatase (AlkP) activity, TPFY was 
more effective in inhibiting AlkP (IC50 = 0.87 µM) than in inhibiting luciferase expression 
(IC50 = 8.0 µM, Figure 4.1). 
It was not possible to use the T47D/A1-2 cell line to test whether or not TPFY 
acts by competing with progesterone for binding to PR. At the high concentrations we 
would need to use, progesterone has the ability to bind the GR that is stably transfected 
into these cells, making it impossible to dissect out the effects on the reporter or AlkP 
due to PR binding. In wild-type T47D cells, there is less GR and expression of AlkP is 
not GR-mediated. We increased the concentration of progesterone 200 fold in this 
assay, expecting to see a loss in inhibition if our compound was a competitive inhibitor. 
TPFY failed to compete with hormone binding in the ligand binding pocket of the 
receptor (Figure 4.2). This finding was corroborated using a competitive binding assay 
with radiolabeled R5020, a synthetic progestin, and purified PR. The relative binding 
affinity (RBA) of TPFY was 0.012%, requiring an IC50 of 11 mM to compete with 10 nM 
hormone (unlabeled R5020 RBA = 100%, data not shown). 
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 We wanted to verify that TPFY was acting through PR and not inhibiting activity 
by directly interacting with luciferase or AlkP protein. 10 µM TPFY, incubated with 
purified luciferase protein, failed to inhibit luminescence in the assay (Figure 4.3). When 
progesterone-treated cell extracts demonstrating AlkP activity were incubated with 10 
µM TPFY, there was no inhibition of activity either. Thus, we conclude that the inhibition  
observed by TPFY is through PR-mediated activity. 
 
TPFY Inhibits Alkaline Phosphatase through Transcription Regulation 
One unique characteristic of AlkP, especially in T47D cells, is that it can be 
assayed for its activity, protein level, and for PR-induced mRNA level. We explored 
these endpoints to evaluate at which step in PR’s genomic action TPFY was acting. By 
treating T47D cells with 10 nM progesterone, and running a quantitative PCR, we 
observed an approximate 12-fold induction of AlkP mRNA (Figure 4.4A). 30 µM TPFY 
downregulated mRNA expression 38%. This was a bit surprising, considering the potent 
inhibition of AlkP enzyme activity observed in the chemiluminescent assays. 
We looked at the protein levels in cells using Western blot analysis. T47D cells 
that were treated with 2.5 nM progesterone plus 10 µM TPFY had 67% less tissue 
nonspecific alkaline phosphatase (TNAP, 80 kDa) protein than cells that were not 
administered TPFY (Figure 4.4B). This data compares to the 10 µM TPFY treatment 
that reduced mRNA levels 32%. From the AlkP profiling, we observed an interesting 
action of TPFY that suggests it may be acting in part through PR-mediated gene 
transcription. 
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TPFY’s Toxicity Verifies Its Druglikeness Potential 
 We addressed a few cellular effects of TPFY before targeting its site of action on 
PR’s genomic activity. General cell toxicity was assessed in PR-negative MDA-MB-231 
breast cancer cells. In an MTS assay, concentrations up to 30 µM had no effect on cell 
proliferation (Figure 4.5A). We did not expect to see toxic effects by TPFY because, in 
the reporter assays, high concentrations of compound poorly inhibited 2 of the 4 
receptors tested. Also, TPFY failed to inhibit GR activity at high concentrations in the 
same cells it successfully inhibited PR. This data validates TPFY’s predicted feasibility 
as a drug based on Lipinski’s Rule of Five (26; 27) (Figure 4.5B). The molecular weight 
(344 g/mol) is under 450, the solubility (logS = -4.01) is greater than PR’s natural ligand 
progesterone, and the cLogP value (1.98) is less than 5.0. These factors all make TPFY 
a positive candidate to navigate through the body and across membranes. Its fragment-
based druglikeness score (-11.89) is much less than zero, which indicates it is 
composed of unique structural characteristics that are not often found in commercial 
drugs. 
Since TPFY was not toxic to cells, it was possible to test whether it could inhibit 
progesterone-dependent cell growth. Though it is difficult to get T47D cells to be 
progesterone-responsive for anchorage-dependent growth, our lab was able to develop 
a reproducible assay to measure this phenomenon (Figure 4.5C). When 1000 cells 
were plated in the wells of a 96-well plate, the absence of progesterone prevented most 
cells from doubling in 4 days. Only 1500 were present, whereas cells treated with 10 nM 
progesterone grew to 2500 in number. 10 µM TPFY did not significantly inhibit this 
progesterone-stimulated cell growth in T47D cells. Although TPFY does not block the 
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growth of these breast cancer cells, it still can serve as a useful tool for dissecting PR 
action in cells. 
 
TPFY Does Not Act by Downregulating PR Levels 
Before we assessed various steps in the genomic action of PR, like nuclear  
localization, dimerization, or DNA binding, we wanted to check if a reduction in PR 
levels was the cause of the inhibition we observed. We treated T47D cells with 
progesterone and 5 µM TPFY. Western blotting with PR monoclonal antibody Ab-8, 
showed that TPFY did not downregulate the levels of PR-B (120 kDa) in cells (Figure 
4.6). Because we find that our compound has no effect on PR protein levels and is 
unable to compete with hormone for binding, yet we see an inhibition of PR-mediated 
gene transcription, we wanted to now assess the intermediate steps of PR acting as a 
transcription factor to determine the site of action for TPFY. 
 
TPFY Does Not Block Nuclear Localization or PR Binding to the PRE 
 We have demonstrated that TPFY downregulates PR-induced mRNA levels in 
cells. An obvious way to inhibit transcription is by blocking receptor binding to DNA. Our 
lab developed a fluorescence anisotropy assay that measures the speed of rotation of a 
complex (indicating its size) based on the excitation and emission of a fluorophore-
bound molecule. PR bound to the fluorescein-labeled consensus response element 
(flcPRE) produced a change of 80 anisotropy units over that of unbound flcPRE (Figure 
4.7). The addition of 2.5-10 µM TPFY had no effect on the change in anisotropy, 
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indicating that this small molecule does not block PR:PRE binding in this real-time 
kinetic assay. 
We then tested whether TPFY affects the cellular distribution of PR. Assuming 
that this small molecule does not disrupt receptor binding to DNA in cells, we treated 
T47D cells with progesterone, with and without 10 µM TPFY, and analyzed nuclear and 
cytoplasmic fractions for PR content (Figure 4.8). Our compound did not affect the shift 
in nuclear accumulation that is typically observed after receptor is bound to a hormone 
agonist. Together, with the in vitro DNA binding assay, this data suggests that TPFY 
might act at the level of coregulator recruitment. 
 
DISCUSSION 
8-(Fluoren-9-yl)-theophylline (TPFY) is a nonsteroidal PR antagonist that 
preferentially inhibits PR compared to other steroid receptors. TPFY inhibits luciferase 
reporter activity in 3 different cells lines and endogenous alkaline phosphatase activity 
in T47D breast cancer cells. It displays 8-fold increased potency on PR compared to 
ER, and very minimal anti-glucocorticoid activity (IC50s = 8.0 µM for PR, 61 µM for ER, 
and too high to measure for GR). Whereas most developed PR antagonists are steroids 
that compete for ligand binding, TPFY is neither a steroid nor competitive inhibitor. Its 
relative binding affinity for PR is less than 0.012% of R5020. 
The major hallmarks of PR genomic action include ligand binding to the LBD, PR 
changing to a conformation that releases it from the chaperone complex, translocation 
into the nucleus, dimerization, binding to DNA, recruitment of coregulators to up or 
downregulate gene transcription, and translation of the target protein. We have found 
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that TPFY does not affect ligand binding to PR, nuclear localization, or PR binding to its 
PRE. However, it does have downstream effects on mRNA levels and thus, target 
protein levels and activity. 
This 8-substituted theophylline displays a very promising lack of anti-
glucocorticoid activity, likely because it is a weak ligand and noncompetitive inhibitor. A 
major unanswered question of glucocorticoid and progesterone action is how different 
whole cell responses arise when both of these receptors can bind to, and activate, the 
same hormone response elements. Because we can show inhibition of PR-mediated 
gene transcription by TPFY, without inhibiting GR activity, TPFY, or more potent 
structurally-related compounds that may be identified based on this lead compound, 
could prove useful in dissecting GR and PR differences in gene regulation. The 
T47D/A1-2 cell line that has comparable levels of PR and GR is an optimal cell line to 
use for this investigation, starting with the induction of luciferase mRNA by both 
hormones. Using TPFY in the “active antagonism” mechanism-based approach, we 
could learn much about the differences in coregulator recruitment that may underlie 
differential transcription by the two receptors.  
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Figure 4.1 Dose-response studies of the inhibition of steroid receptor transactivation by 
TPFY. For each receptor, induction of luciferase reporter gene expression in the presence of an 
appropriate hormone ligand was assayed in stably transfected cells as described in the 
Experimental Procedures. Cells were incubated for 24 h with 5 nM P4 for PR (circles), 0.2 nM 
E2 for ERα (triangles), 2.5 nM DEX for GR (squares), 80 pM DHT for AR (diamonds), and the 
indicated concentrations of TPFY (or DMSO vehicle). For each receptor, these hormone 
concentrations induced ~80% of maximal activity. Treatments with DMSO minus TPFY in each 
respective assay were set to 100%. Data are the average ± SEM for at least three independent 
experiments. 
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Figure 4.2 High concentrations of progesterone do not reduce the ability of TPFY to 
inhibit alkaline phosphatase activity. Progesterone:PR activation of endogenous AlkP activity 
was evaluated from dose response studies in T47D cells. Cells were maintained in 2.5 nM (filled 
circles) or 500 nM (open circles) P4 with the indicated concentrations of TPFY for 24 h. Activity 
in the presence of P4 with DMSO and no inhibitor was set to 100%. Data represent the mean ± 
SEM of at least three experiments. IC50 values were calculated by curve fitting using Sigma Plot. 
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Figure 4.3 TPFY does not directly inhibit luciferase or alkaline phosphatase proteins. 
Assays using pure luciferase protein or cell extract (for AlkP) were conducted to test whether 
the inhibition of their activities was due to a direct effect on the proteins without TPFY acting 
through PR. 0.05 ng of luciferase was incubated with and without 10 µM TPFY and measured 
for luminescence (empty bars). For AlkP, T47D cells were treated with (black bars) or without 
(gray bars) 2.5 nM P4 for 24 h. Extract was incubated with TPFY for 15 min in assay buffer and 
measured for AlkP activity using a chemiluminescent substrate as described in the Experimental 
Procedures. Data represent the mean ± SEM of at least three experiments. 
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Figure 4.4 TPFY inhibits alkaline phosphatase in part by reducing PR-mediated gene 
transcription. (A) Transcription of AlkP was induced with 10 nM P4. T47D cells were treated 
with the indicated concentrations of TPFY and harvested after 24 h. RNA isolation and 
quantitative RT-PCR was performed as prescribed in Experimental Procedures. Data represent 
the mean ± SEM of at least three experiments. (B) Western blot was used to analyze AlkP 
levels in T47D cells. Cells were treated with 2.5 nM P4 with or without 10 µM TPFY for 20 h. 
Cells were harvested and 20 µg of protein was analyzed according to the Experimental 
Procedures. Tissue nonspecific alkaline phosphatase (TNAP, 80 kDa) was probed using 
monoclonal antibody alkaline phosphatase F-4.  
 
(A)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
          (B) 
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Figure 4.5 Effects of TPFY on cell viability support its druglikeness score. (A) General 
toxicity of TPFY was assayed using PR- and ER-negative MDA-MB-231 breast cancer cells. 
Cells were maintained in medium containing the indicated concentrations of TPFY or P4 for 3 
days and viability was assayed as described using the MTS assay. (B) Druglikeness parameters 
for P4 and TPFY were scored based on Lipinski’s Rule of Five (26), as described in Chapter 3. 
(C) TPFY’s ability to block progesterone-responsive cell growth was assayed in T47D cells. 
1000 cells were seeded in a 96-well plate and treated with 10 nM P4 and 10 µM TPFY for 4 
days. Cell growth was measured using the MTS assay. Data represent the mean ± SEM for at 
least six replicates at each concentration.  
 
Parameter  P4  TPFY 
Molecular 
Weight (g/mol)  299  344 
Solubility 
(logS)  -4.36  -4.01 
Hydrophilicity 
(cLogP)  3.69  1.98 
Druglikeness  0.59  -11.89 
(A)                                                                (B) 
 
 
 
 
 
 
 
 
 (C) 
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Figure 4.6 Western blot analysis of PR levels in T47D cells treated with TPFY. Cells were 
treated with 2.5 nM P4 (or ethanol vehicle) and 5 µM TPFY (in 0.3% (v/v) DMSO) for 20 h. Cells 
were harvested and 20 µg of protein was analyzed by Western blot according to Experimental 
Procedures. Progesterone receptor was probed using monoclonal antibody Ab-8 (PR-B, 120 
kDa). 
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Figure 4.7 TPFY does not inhibit PR binding to flcPRE. FAMA was carried out in 96-well 
black wall microplates as described in Experimental Procedures. Samples contained 11 nM 
purified full length human PR-B, fluorescein-labeled consensus PRE/GRE oligonucleotide 
probe, 100 nM P4, and the indicated concentrations of TPFY. 11 nM PR-B is enough receptor to 
saturate ~80% of the flcPRE. Anisotropy change is the increase in anisotropy observed after 
progesterone:PR binds to the flcPRE. Data represent the mean ± SEM for three independent 
experiments. 
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Figure 4.8 TPFY does not alter nuclear localization of PR in T47D cells. Cells were treated 
with 10 nM P4 with or without 10 µM TPFY for 1 h. Cells were harvested and cytoplasmic 
(empty bars) and nuclear (filled bars) fractions were collected and assayed by western blot as 
described in Experimental Procedures. Relative levels of PR (120 kDa) were calculated by 
PhosphorImager quantitation of band intensity and normalized to α-tubulin (50 kDa) or lamin C 
(63 kDa). 
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CHAPTER V: 
DISCUSSION 
 
Progesterone plays a pivotal role in reproductive development, but its 
involvement in disorders such as endometriosis and breast and uterine cancers is not 
well understood. Progesterone works through the progesterone receptor (PR), a 
member of the steroid receptor family of transcription factors. PR often works in concert 
with estrogen receptor (ER) and regulates genes that are also controlled by 
glucocorticoid receptor (GR) (1; 2). As a result, therapeutics that target PR often exhibit 
unwanted cross-reactivity with other steroid receptors. 
Selective progesterone receptor modulators (SPRMs) have been developed for 
clinical use in contraception, hormone replacement therapy in post-menopausal women, 
and hormone-dependent cancers (3; 4). They are usually assigned to one of three 
groups, based on whether they block receptor binding to DNA and whether they are 
pure antagonists. Type I PRMs are pure antagonists that hinder DNA binding. Type II 
and type III modulators allow DNA binding, but the former displays partial agonist 
activity depending on the tissue and cellular conditions. 
An ideal inhibitor of PR action would be selective for PR genomic or extra-
nuclear activity, demonstrate limited cross-reactivity with other steroid receptors, and 
exert minimal toxicity, while blocking tumor growth or triggering apoptosis in target 
tissues. While no current inhibitor meets this ideal in all categories, current drug 
candidates seek to achieve the best balance between these properties.   
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Our lab initially used an in vitro fluorescence anisotropy assay to screen for small 
molecule inhibitors that block PR binding to its DNA response element. Candidate 
inhibitors were selected for further evaluation if they inhibited PR:PRE binding, but not 
ER or androgen receptor (AR) binding to their consensus sequences. TBPM was one 
small molecule inhibitor of ER activity identified from the screen (5). While further 
characterizing this analogue of theophylline, we pursued structure-activity relationship 
studies to find more potent and selective inhibitors of steroid receptor action. 
Theophylline, a close relative of caffeine, is a drug used primarily for respiratory 
diseases like asthma and chronic obstructive respiratory disease (COPD) (6; 7). 
Although theophylline is no longer the primary first-line of defense drug it once was, 
studies over the decades have explored derivatives of the theophylline for a wide use of 
applications in neuropathology, pulmonary disease, and carcinomas (8–10). The 
analogues of theophylline we studied, including TPBM, were originally synthesized to 
study their depression of the central nervous system (11; 12). We explored structural 
motifs that would confer preference for inhibiting one steroid receptor over the others. 
Here, I describe two distinct motifs that result in preferential inhibition of PR relative to 
ER, GR, and AR. A set of 8-alkylthio-6-thio-substituted theophyllines with additional 
saturated carbon-chain branching exhibited higher potency, but less cross-reactivity 
than an 8-substituted theophylline with a polycyclic aromatic hydrocarbon fluorenyl 
group. 
Structure-activity relationship (SAR) studies are a useful way to develop the most 
effective compound from its parent, while targeting the moiety that confers its action. As 
specific changes are made in chemical structure, the effects on biological activity are 
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assessed. When our initial PR inhibitors were identified, there were ~55 closely related 
derivatives that allowed us to trace an SAR trend. The addition of sulfurs, which 
increase lipophilicity, improved overall efficacy of the compounds. O-6 was replaced 
with sulfur and an 8-alkyl group with a sulfur linker gave the best outcome in our cell-
based reporter assay. Alkyl chains 4 to 7 carbons in length increased preference for PR 
inhibition, whereas shorter chains were nonspecific and longer chains were more potent 
ER inhibitors. Adding methyl and ethyl branching to this 8-alkylthio group also improved 
PR inhibition. 
6-Thio-8-(isopentyl)thiotheophylline (PR48), 6-thio-8-(2-ethylbutyl)thio-
theophylline (PR51), and 6-thio-8-(2-ethylhexyl)thiotheophylline (PR52) represent a set 
of small molecule inhibitors selective for PR action. These compounds are 
noncompetitive inhibitors that block PR-mediated gene transactivation, in part, by 
altering the cellular distribution of activated receptor. Treatment of T47D breast cancer 
cells with representative compound PR51 showed a reduction in nuclear localization of 
hormone-bound PR and a lack of receptor recruitment to the PRE in the PR-inducible 
sgk1 gene.  
8-(Fluoren-9-yl)theophylline (TPFY) is another analogue of theophylline that 
exhibits moderate potency and an impressive lack of cross-reactivity with other 
receptors. It potently inhibited progesterone-induced endogenous alkaline phosphatase 
activity. This small molecule does not block PR binding to DNA in vitro, nor does it alter 
cellular distribution of the receptor in T47D cells. An IC50 for inhibition of GR could not 
be calculated because TPFY failed to significantly inhibit GR induced transactivation at 
all tested concentrations, including 50 µM. Its mechanism of action remains to be 
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elucidated, but this compound stands to serve as a probe for differentiating PR and GR-
mediated gene regulation. 
As demonstrated from this work, one parent compound (theophylline) can give 
rise to a diverse set of small molecule inhibitors. Although original uses for theophylline 
were in pulmonary medicine, analogues of this small molecule have far reaching 
applications and diverse modes of action. In our lab, we study their effects for use in 
endocrine-related cancers and as research tools for steroid receptor action. TPBM 
blocks DNA binding, and another derivative, TPSF (13), promotes degradation of ER. 
One set of compounds described in this work (PR48, PR51, and PR52) are pure 
antagonists that work, in part, by altering nuclear localization of PR. This might involve 
direct interactions with an allosteric site on the receptor, the induction of an antagonist-
like conformational change, or an indirect interaction with other factors in PR action. 
Moreover, a combination of these activities could produce the inhibition we observed. 
TPFY, although its mechanism is not fully understood, does not appear to work in the 
same way as the 8-alkylthio-6-thiotheophyllines. Nevertheless, these analogues of 
theophylline show promise as useful tools for dissecting progesterone receptor action, 
independent of it physiological counterparts, especially estrogen receptor and 
glucocorticoid receptor. 
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